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ABSTRACT OF DISSERTATION 
 
 
NITRATION AND INACTIVATION OF MANGANESE SUPEROXIDE DISMUTASE 
PLAYS A CRITICAL ROLE IN METABOLIC SWITCH  
 
 Alzheimer’s disease (AD) is a multifactorial, progressive, age-related 
neurodegenerative disease.  Oxidative stress hypothesis is most prevalent and is gaining 
significant support.  Inspite of the progress achieved on oxidative stress related damages 
in AD brain; the modification occurring on the various cellular antioxidant enzymes 
antioxidant has not been identified.  Tyrosine nitration, a marker for peroxynitrite 
induced oxidative damage to protein is widespread in AD brain and Manganese 
superoxide dismutase (MnSOD), primary mitochondrial antioxidant enzyme is prone to 
peroxynitrite induced nitration and inactivation.  Nitration of proteins involved in energy 
metabolism has been demonstrated in AD brain, which may explain the altered glucose 
metabolic status existing in AD brain.  In the present study, we investigated the effect of 
tyrosine nitration of MnSOD on energy metabolism by the use of AD mouse model and 
cultured neuronal cells.  The AD mouse model was generated from a double homozygous 
knock-in mouse, designated as APP/PS-1 mice, by incorporating the Swedish familial 
AD mutations in APP and P264L familial AD mutation in PS – 1.  These animals 
develop age dependent increase in Aβ deposition beginning at 6 months along with an 
increase in insoluble Aβ1-40/Aβ1-42 levels.  Genotype and age associated increase in 
nitration of MnSOD without any change in protein levels was also observed.  MnSOD 
activity and mitochondrial respiration was decreased in APP/PS-1 mice.  There was also 
concomitant increase in levels of lactate, an index of glycolytic activity in APP/PS-1 
mice.  To directly investigate the role of MnSOD inactivation in mitochondrial function 
and subsequent alteration in glycolytic activity, SH-SY5Y neuroblastoma cells line was 
used and treated with peroxynitrite.  Enhanced nitration and reduction in the activity of 
MnSOD was observed upon peroxynitrite treatment.  Peroxynitrite treatment also 
induced mitochondrial dysfunction, but MnSOD was inactivated at a concentration of 
peroxynitrite 10 times lower than that required to inhibit mitochondrial respiration.  
Mitochondrial dysfunction was alleviated by SOD mimetic and reproduced by MnSOD 
siRNA.  The decline in mitochondrial function did not result in decreased ATP levels but 
was accompanied by an up-regulated glycolysis signified by high levels of lactate and 
lactate dehydrogenase activity but decreased activity of pyruvate dehydrogenase.  These 
changes were prevented by SOD mimetic and were promoted by MnSOD siRNA.  
Specific reduction of MnSOD in MnSOD heterozygous knock-out mice resulted in 
decreased RCR and complex I activity with increased lactate levels.  Taken together, 
these data demonstrate a critical role of MnSOD in influencing the mitochondrial 
function and thereby the switch in the energy metabolism switch that might occur under 
the pathological condition of MnSOD deficiency.   
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CHAPTER ONE 
 
NEURODEGENERATIVE DISEASE, ALZHEIMER’S DISEASE, MANGANESE 
SUPEROXIDE DISMUTASE AND PEROXYNITRITE 
 
INTRODUCTION 
 
The mammalian brain occupies a relatively small percentage of body weight (2%) 
but consumes an inordinate fraction (20%) of total body oxygen consumption.  Oxygen 
supply is essential for the maintenance of cellular respiration and the production of 
energy in the brain.  ATP produced in the mitochondria, by complete oxidation of 
glucose to carbon-dioxide and water in the presence of oxygen, is the obligate energy 
source of the brain.  In the process of production of energy in mitochondria, incomplete 
reduction of oxygen can form superoxide radicals and subsequent reactive oxygen 
species (ROS) capable of damaging macromolecules.  Brain is particularly sensitive to 
ROS owing to its high level of oxygen consumption and inadequate anti-oxidant defenses 
(Floyd and Carney, 1992).  Oxidative stress hypothesis has been proposed and is gaining 
momentum towards unraveling the pathogenesis of neurodegenerative diseases including 
Alzheimer’s disease (AD) (Markesbery, 1997).  Oxidative stress is evidenced by protein 
oxidation, lipid peroxidaton (Butterfield and Lauderback, 2002), 3-nitrotyrosine (3-NT) 
levels (Castegna et al., 2003; Smith et al., 1997), advanced glycation end products and 
DNA/RNA oxidation products (Mecocci et al., 1994).  Peroxynitrite is a consistent 
mediator of 3-NT formation (Smith et al., 1997; Yamakura et al., 1998).  Manganese 
superoxide dismutase (MnSOD), the primary anti-oxidant enzyme in the mitochondria is 
highly sensitive to peroxynitrite induced nitration of its tyrosine residues and thereby 
becomes inactivated (MacMillan-Crow et al., 1996; Yamakura et al., 1998).  Because 
mitochondria are the major source of superoxide production under physiological 
conditions, the function of MnSOD in catalyzing the dismutation of superoxide to 
hydrogen and molecular oxygen is vital in preventing any accumulation of superoxide 
and thereby oxidative stress.  Studies from our lab have demonstrated that MnSOD 
protects mitochondrial function (Yen et al., 1999).  Thus, inactivation of MnSOD 
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presumably would lead to a compromised mitochondrial function and thereby reduction 
in cellular energy production from oxidative phosphorylation.  Interestingly, in tumors 
and transformed cells, glycolysis is known to compensate for the loss of mitochondrial 
function in producing energy for cellular processes (Gatenby and Gillies, 2004).  
However, whether similar compensation will occur in non-tumor brain tissue is unclear.  
The following review will focus on the existence of oxidative stress in Alzheimer’s 
disease, its consequence on MnSOD activity, mitochondrial function and glycolysis and a 
possible role for MnSOD in these alterations.  
 
NEURODEGENERATION AND NEURODEGENERATIVE DISEASES (NDD) 
 
 It is estimated that almost 400 million individuals suffer from neurological 
diseases in the world (Welsh, 2006b).  The word “Neurodegeneration”, is etymologically 
comprised of ‘neuro’, designating nerve cells, and ‘degeneration’, referring to a process 
of losing structure or function.  Thus, it refers to any pathological condition primarily 
affecting neurons (Przedborski et al., 2003).  NDD are a heterogeneous group of 
disorders characterized by gradual progression, selectively affecting specific subsets of 
neuronal populations in specific functional anatomic systems (Lin and Beal, 2006).  The 
inciting or the causative factors of NDD are not clearly understood, but NDD are known 
to progress relentlessly and are always related to neurons.  So, neoplasm, edema, 
hemorrhage and trauma of the nervous system are not neurodegenerative diseases and 
neither is multiple sclerosis, which does not affect neurons but affects the myelin sheath. 
There are hundreds of known NDD and many of these overlap with each other 
clinically and pathologically rendering the classification challenging (Burn and Jaros, 
2001).  To avoid confusion, the classification is based on predominant clinical feature or 
topography of the predominant lesion.  Accordingly, NDD of the CNS is grouped into 
those of the cerebral cortex, the basal ganglia, the brain stem and cerebellum.  But each 
group is represented by more than one disease, so within each group, a given disease is 
further classified based on its main clinical features.  For example, the cerebral cortex 
group includes dementing and non-dementing disorders, Alzheimer’s disease being the 
predominant dementing disorder.  Diseases affecting the basal ganglia are characterized 
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by abnormal movements classified as hypokinetic or hyperkinetic.  Parkinson disease is 
hypokinetic disease while Huntington disease is an example of a hyperkinetic disorder.  
Cerebellar diseases comprise three main neuropathological types: cerebellar cortical 
atrophy, pontocerebellar atrophy and Friedreich ataxia.  Spinal cord NDD includes 
Amyotrophic lateral sclerosis and spinal muscular atrophy (Przedborski et al., 2003).  
With the dawn of molecular biology and advent of state-of-the-art techniques in the past 
two decades, the classification of NDD, presently is based on molecular characteristics.  
Neuropathological entities that formerly belonged to very different categories are now 
grouped together because of common molecular defects have been identified. This 
classification has given rise to the groups of trinucleotide-repeat diseases (Cummings and 
Zoghbi, 2000), prion diseases (Prusiner, 1998), synucleinopathies (Galvin et al., 2001) 
and tauopathies (Goedert and Spillantini, 2001).   
Though a great many NDD have been identified, no clear cut picture about the 
causes has emerged.  A risk factor that is consistently linked to the development of NDD 
is ageing.  The probability of developing a neurodegenerative disorder dramatically 
increases in the sixth, seventh and eighth decades of life.  There is a high probability that 
a person who lives to the age of 85 years will suffer from Alzheimer’s disease (AD).  
Parkinson’s disease (PD) is most common in those above the age of 70 years and the 
probability of developing amyotrophic lateral sclerosis (ALS) rises sharply above the age 
of 40 years (Mattson and Magnus, 2006).  The relative contribution of genetic and 
environmental factors to the etiology of NDD has been a subject of intense research.  The 
genetic basis was suggested based on findings of familial occurrence of NDD.  The 
genetic causation can be autosomal dominant trait (Huntington disease), autosomal 
recessive trait (familial spastic paraparesis), an X-linked trait (spinal and bulbar muscular 
atrophy) or a maternally inherited trait.  Sporadic experienced are also being thoroughly 
studied.  Oxidative stress has emerged as an important factor in mediating the effect of 
many environmental and pathological conditions.   
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ALZHEIMER’S DISEASE AND ITS PREVALENCE 
 
Despite enjoying the longevity nowadays, people have to be aware of the fact that 
the chances of suffering from dementia would be higher in their senior years.  Dementia 
may be caused by more than 60 different diseases, and affects a significant proportion of 
the elderly population (Welsh, 2006b).  Alzheimer’s disease (AD), the most common of 
the dementias, is estimated to account for approximately 60 percent of all dementia 
(Small et al., 1997). Alzheimer’s disease, named for Alois Alzheimer, who first described 
in 1907, the findings of senile plaques and neurofibrillary tangles in the hippocampus and 
neocortex of a middle aged woman with memory deficits and progressive loss of 
cognitive function.  Estimates of numbers affected worldwide are greater than 18 million 
(http://www.alzheimer’s.org), with over 5 million people living in the USA. The 
epidemic of AD is expected to quadruple by the year 2047.  The greatest risk factor for 
AD is aging with the prevalence of this disease doubling every 5 years after age 65 and 
approaches 50% by age 85.  Although AD is not caused by aging, nor is it an inevitable 
part of the aging process, it is age-related (Welsh, 2006b).  With the proportion of elderly 
people in the population increasing steadily, and an expected three quarters of the world 
population over 60 years of age by 2025                        
(http://www.who.int/ageing/ActiveAgingPolicyFrame.pdf), the financial, societal and 
emotional costs of AD will be staggering.   
AD is a complex age-related neurodegenerative disorder, with retrograde 
progressive amnesia that is mentally and physically completely debilitating (Dawbarn 
and Allen, 2007).  AD is a slow disease, starting with mild memory loss and ending with 
severe dementia.  As the neuronal cells die slowly, the individual’s ability to function 
worsens progressively leading eventually to a loss of most functional skills, including the 
ability to read, reason, communicate and understand spatial relationships.  The course the 
disease takes and speed of progression vary from person to person.  On an average, AD 
patients live from 8 to 10 years after they are diagnosed, though the disease can last for as 
many as 20 years.  Brain regions involved in learning and memory processes, including 
the temporal and frontal lobes, are reduced in size in AD patients as the result of 
degeneration of synapses and death of neurons.  Because there can be other causes of 
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memory loss, definitive diagnosis of AD requires postmortem examination of the brain, 
which must contain sufficient numbers of "plaques" and "tangles" to qualify as affected 
by AD (Mattson, 2004).   These are the classical hallmark pathologies of Alzheimer’s 
disease as observed by Alois Alzheimer (1864 – 1915) and subsequent researchers 
(Dickson, 2001).  Apart from this, selective neuronal loss and shrinkage, atrophy of the 
brain, synapse loss, neuropil thread formation and amyloid angiopathy are also 
manifested in AD brain.  A definitive diagnosis cannot be made without 
neuropathological confirmation.  The core of neuritic plaques is composed of β-amyloid 
(Aβ) that has aggregated into densely packed, insoluble, β-pleated sheets (Peskind, 1996), 
with dystrophic neurites, abnormal synapses, activated microglia and fibrous astrocytes 
located on the periphery.  Neurofibrillary tangles (NFT) mainly consist of paired helical 
filaments that are predominantly composed of abnormally phosphorylated tau protein 
(Peskind, 1996).   
Aβ is normally dissolved in the extracellular fluid of the brain and cerebrospinal 
fluid.  But under certain circumstances, it forms into small fibrils which adopt a β-sheet 
formation, that precipitate out of solution as fibrillar aggregates and are deposited 
extracellularly as plaques.  Aβ plaques vary in size from about 5 to 200 μm across and 
can be divided as diffuse or neurotic plaques based on their structural appearance.  
Diffuse plaques consist of homogeneous deposits of fibrillary material without any local 
reactive glial cells or abnormal neuritic processes.  Neuritic plaques have a more 
heterogeneous sculpted appearance with a central dense core, with peripheral halo.  The 
main component of diffuse plaques is Aβ42 whereas Aβ40 predominates in neuritic 
plaques.  The halo contains additional elements in the form of glial and abnormal swollen 
neuritic processes.  The glial component consists mainly of astrocytic processes and of 
microglial cells.  The formation of Aβ plaques is not entirely specific for AD but also 
occur in normal aging, Down’s syndrome and some other neurodegenerative diseases.  
The essential difference between AD and normal aging with respect to plaques is that 
they are more numerous in AD.  Although neuritic plaques are composed predominantly 
of Aβ, many other molecules are also seem to be concentrated in them.  Some of the 
proteins include enzymes acetylcholinesterase (Mesulam and Asuncion Moran, 1987) and 
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α1 – antichymotrypsin (Abraham et al., 1988), complement components (Eikelenboom 
and Stam, 1982), apolipoproteins and growth factors and their receptors.     
 
NEURITIC PLAQUES 
 
The amino acid sequence of Aβ, the predominant content of neuritic plaque, was 
first obtained from cerebrovascular amyloid (Glenner and Wong, 1984).  The plaque core 
of amyloid protein from the cerebral cortex of AD brain was also purified and 
characterized and found to be similar to that of amyloid of cerebrovascular origin found 
in the brains of Down’s syndrome patients.  In all cases Aβ was found to consist of 40 – 
42 amino acid sequence.  In 1987, Aβ peptide was shown to be derived from a larger 
precursor, amyloid precursor protein (APP) (Figure 1.1) (Goldgaber et al., 1987) and the 
gene was later localized to the long arm of chromosome 21.  APP is synthesized in the 
endoplasmic reticulum (ER) and glycosylated within the ER and Golgi apparatus.  This is 
a type I transmembrane glycoprotein with a relatively long N-terminal extracellular 
domain and a short C-terminal cytoplasmic domain.  Of the 18 exons which encode for 
APP, exons 7, 8 and 15, encoding the extracellular domain, are subject to alternative 
splicing.  There are seven known splice variants of the protein; major isoforms being 695, 
751 and 770 amino acids (aa) in length.  APP is expressed in all tissues, but the exclusive 
isoform expressed in neurons of the central and peripheral nervous system is APP695 
(Dawbarn and Allen, 2007), whereas 751 aa and 770 aa transcripts are expressed both in 
neural and non-neural cells (Selkoe, 1996).  A battery of functions has been attributed to 
APP including neurite outgrowth, cell adhesion molecule, synaptogenesis and cell 
survival (Magara et al., 1999; Perez et al., 1997).  
Aβ domain is present between the amino acids 672 and 712/714 of APP which 
can undergo concerted endoproteolytic cleavage by several proteases namely α, β and γ 
secretase in either a non-amyloidogenic pathway (NAP) or amyloidogenic pathway (AP) 
depending on the sequence of action of secretases.  In NAP, the APP is first cleaved by   
α-secretase, whose activity is ascribed to the members of ADAM (a disintegrin and 
metalloprotease) family of proteases (ADAM 17, ADAM 10 and ADAM 9) (Dawbarn 
and Allen, 2007), resulting in secretion of an N – terminal ectodomain fragment called 
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Figure 1.1   Processing of Amyloid precursor protein (APP)
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sAPPα, and the retention of an 83 aa C – terminal fragment called C83 tethered to the 
membrane.  α-secretase cleaves APP at amino acids 687/688, thereby precluding the 
formation of Aβ.  sAPPα may be involved in the enhancement of synaptogenesis, neurite 
outgrowth and neuronal survival, and is considered to be neuroprotective. 
In AP the APP is cleaved by β-secretase between 671/672 aa producing a N 
terminal fragment called sAPPβ and a C terminal fragment of C99 attached to the 
membrane.  A sequential cleavage of C99 by γ-secretase leads to the formation of Aβ of 
length 40 or 42 aa (Aβ40 or Aβ42).  Under normal conditions very small amounts of 
Aβ1-40 and Aβ1-42 are formed in the cell; in both CSF and cell culture Aβ1-40 is the 
major component (50% - 70%), with Aβ1-42 as the minor component (5% - 20%) 
(Murphy et al., 1999).  Neuronal and non-neuronal cells process APP differently.  The α-
secretase pathway predominates in non-neuronal cells and so little of Aβ is produced.  
 
NEUROFIBRILLARY TANGLES (NFT) AND AD 
 
The primary component of NFTs is the Tau protein.  Tau is a microtubule 
associated protein (MAP) that maintains the microtubule network in neurons for axonal 
transport.  Tau is expressed throughout the central nervous system, but predominantly in 
neuronal axons.  MAP1A/MAP1B, and MAP2 are the other proteins required to promote 
assembly and stabilization of microtubules.  Tau is the smallest, with a biological activity 
depending on phosphorylation of normally present 2-3 mole of phosphate/mole of protein 
for optimal activity (Kopke et al., 1993).  To date, the most established and the most 
compelling cause of dysfunctional tau in AD is the abnormal hyperphosphorylation of tau 
leading to accumulation of tau as intraneuronal tangles of paired helical filaments 
(PHFs), twisted ribbons and/or straight filaments (SF) (Iqbal et al., 2000).  The 
hyperphosphorylation of tau can be due to a conformational change (Jicha et al., 1997) in 
diseased brain, making it a better substrate for phosphorylation and/or a worse substrate 
for dephosphorylation. The most important factor for the hyperphosphorylation of tau is 
the imbalance between tau kinases and/or phosphatases in the favor of the former (Pei et 
al., 2003). Abnormally hyperphosphorylated tau isolated from AD brain polymerizes into 
PHF/SF tangles in vitro at pH 6.9 under reducing conditions (Alonso et al., 2001), 
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consistent with findings in AD brain.  The hyperphosphorylated tau sequesters normal tau 
and other MAPs causing inhibition and disassembly of microtubules and microtubular 
network leading to neurodegeneration.  
 
CLASSIFICATION OF ALZHEIMER’S DISEASE 
 
Classification of AD is based on the age of onset and hereditary characteristics.  
Two main types have been identified, Familial AD (FAD) and Late-Onset AD (LOAD).  
The onset of FAD is early (< 60 years) and demonstrates an autosomal dominant pattern 
of inheritance.  The age of onset of LOAD is over 60 years of age and is characterized by 
a complex pattern of inheritance.  Mutations in three genes, APP, presenilin 1 (PS-1) and 
PS-2 are causatively linked with the pathogenesis of FAD by affecting the production of 
Aβ (Goate et al., 1991; Selkoe, 1997; Sherrington et al., 1995).  The presenilins PS1 and 
PS2 most likely, together with three additional subunits (Nicastrin, Anterior pharynx 
defective 1 homologue and Presenilin enhancer 2 homologue), provide the catalytic 
subunit of γ-secretase (Kimberly et al., 2003) that is involved in processing of APP to Aβ.  
Most of the mutations that cause FAD increase production of both Aβ40 and Aβ42 or 
selectively increase the production of Aβ42 (Selkoe, 1997).  FAD represents less than 1% 
of all AD cases.   
Goate et al., (Goate et al., 1991) reported first that mutations in APP cause FAD, 
followed by identification of 19 missense mutations in this gene to account for a small 
portion of FAD cases (about 10%).  Most of these mutations occur at the β or γ secretase 
cleavage sites.  Mutation at γ secretase cleavage site increases the ratio of Aβ42 to Aβ40 
(De Strooper and Annaert, 2000), whereas mutation at β secretase cleavage site (Swedish 
mutation) results in an increase in total Aβ species without altering the ratio.  The PS1 
gene contains 12 exons and is located in the long arm of chromosome 14, while PS2 is 
located on chromosome 1 and also has 12 exons.  After the initial identification of 5 
missense mutations on PS-1 by Sherrington et al., (Sherrington et al., 1995), over 130 
mutations have been reported accounting for a large proportion of FAD cases.  Mutations 
in PS1 increase the ratio of Aβ42 to Aβ40 and result in very early onset of AD (26 - 60 
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years) (Dawbarn and Allen, 2007).  In contrast, only eight FAD mutations have been 
identified on PS2 and result in late onset AD (40 – 75 years).   
Although a clear picture seems to exist about the genetic risk factors for FAD, the 
majority of AD cases are late onset.  To date, APOE is the only known genetic risk factor 
and has been consistently associated with risk for LOAD in many studies (Finckh, 2003).  
Of the three isoforms (APOE2, APOE3, APOE4), the presence of APOE4 increases the 
risk in a dose dependent manner.  Nearly all individuals homozygous for the APOE4 will 
develop AD by 80 years of age (Corder et al., 1993). 
 
ETIOPATHOGENESIS OF AD 
 
Narrowing down to a single unique causative factor for AD pathogenesis is a 
challenge, as being a multifactorial disorder well defined genetic factors as well as 
numerous potential environmental variables play contributory roles (Welsh, 2006a).  For 
the naked eye, the brain in cases of AD appears atrophied and externally the brain usually 
shows gyral narrowing and sulcal widening, while an increase in ventricular size is 
noticed in cerebral slices (Dawbarn and Allen, 2007).  Even though the single most 
important factor which accounts for the clinical symptoms of AD is loss of neuronal 
synapses and neuronal cell death, understanding of the causation of neuronal loss is 
confounded by the selective neuronal vulnerability exhibited by the neurons of neocortex 
and hippocampus.  Characteristically a 40% reduction in the pyramidal neuron density of 
neocortex, 68% loss in hippocampal CA1 neurons, 40-70% loss of neurons in basal 
nucleus and 40% and 55% loss of neurons in dorsal raphe and locus coeruleus 
respectively, have been reported (Arendt et al., 1983; Terry et al., 1981).  However, the 
exact pathomechanism leading to neuronal death is not clear.  As excessive deposition of 
Aβ as senile plaques throughout the cerebral cortex is one of the pathological hallmarks 
of AD, much effort has been made to understand the mechanisms of AD neuropathology 
and the role of APP processing into Aβ.  Being one of the key pathological features of 
AD, Aβ plaque has been proposed to be a primary cause for neuronal cell loss.   
This proposal gained credence by the observations of Aβ plaques surrounded by 
degenerating neurons (Katzman and Saitoh, 1991),  Aβ peptides being toxic to neurons in 
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culture (Aksenov et al., 1998; Varadarajan et al., 1999; Yankner et al., 1989) and the 
increased deposition of Aβ due to mutations in APP and presenilin genes.  Multiple 
mechanisms have been advanced for Aβ induced cell death.  They are inflammatory 
response and release of neurotoxic cytokines, excessive release of excitatory amino acids 
like glutamate from glial cells, inhibition of axonal and dendritic transport and synaptic 
dysfunction and loss (Bossy-Wetzel et al., 2004). Though these do not point out precisely 
the mechanism of Aβ induced cell death, current literature suggests that one of the main 
points of commonality amongst these is that oxidative stress is the mediator of neuronal 
death or apoptosis.  Mechanisms others than oxidative stress mediating neuronal cell 
death have also been under intense investigation, but evidence of oxidative stress in AD 
pathology are abundant and compelling.   
AD brain is under intense oxidative stress manifested by increased protein 
oxidation, lipid peroxidation, increased levels of 4 – hydroxynonenal (HNE) (Lovell et 
al., 1997), free radical formation (Butterfield and Lauderback, 2002), increased levels of 
isoprostanes (Montine et al., 1998), 3-nitrotyrosine (3NT) levels (Castegna et al., 2003; 
Smith et al., 1997), dityrosine (Hensley et al., 1998; Smith et al., 1997),  advanced 
glycation end products and DNA/RNA oxidation products (Mecocci et al., 1994).  The 
neurotoxic trace element hypothesis in AD is relevant to the oxidative stress observed in 
AD (Markesbery, 1997).  Aluminium, mercury and iron have received most attention, of 
these, iron (Fe) has the most pathophysiologic role as catalyst for free radical generation.  
This is by virtue of its loosely bound electron, ability to exist in more than one valence 
state (Markesbery, 1997) and higher levels of Fe in brain (Floyd, 1999).  Some of the 
reactions that lead to production of oxidants are illustrated in Table 1 [Adopted from 
(Welsh, 2006a)].  Aβ, in ways that are inhibited by free radical antioxidants like vitamin 
E, cause brain cell protein oxidation, lipid peroxidation and ROS formation, among other 
oxidative stress responses, suggesting that this peptide is a source of oxidative stress in 
AD brain (Butterfield et al., 2001).  The findings that Aβ  is central to the pathogenesis of 
AD (Selkoe, 2001) and that the AD brain is under significant oxidative stress were united 
into a comprehensive model for neurodegeneration in the brain in AD based on Aβ-
associated free radical generation (Butterfield and Lauderback, 2002).   
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Table 1.1 Mechanisms leading to protein oxidation observed in AD, adopted from 
Welsh, 2006a 
 
Chemistry Oxidant Mechanism 
Fenton reaction Hydroxyl radical H2O2 + Fe
2+            OH
.
 + Fe3+ + OH
-
 
Haber-Weiss 
reaction 
Hydroxyl radical 
O2
.-
 + H2O2 + Fe3+/ Fe2+           OH
. + OH
-
 + 
O2 
Nitration Peroxynitrite 
O2
.-
 + NO
.
           ONOO
_
 and  
ONOO
_  
+ H+           ONOOH          OH
. + 
NO2 
Metal catalyzed 
oxidation  (MCO) 
H2O2 
2e- (metal e- donor) + O2 + 2H+                H2O2 
and 
H2O2 + protein (lys) ligated Fe2+               protein 
alkyl radicals 
NADPH oxidation Superoxide 2O2 + NADPH           2O2
.-
 + NADP+ + H+ 
Glycation 
Glucose and 
reactive 
intermediates 
(H2O2 and OH
.
) 
 
Protein products + glucose         Schiff base + 
Maillard + glycated protein advanced 
glycation end products 
Tyrosine oxidation 
Tyrosyl radical 
(TyrO
.
) and 
tyrosine peroxide 
(TyrOOH) 
                   Peroxide 
2Tyr + H2O2                2TyrO
.
 + 2 H2O 
2TyrO
.
 + O2
.-
 + H+               2TyrOOH 
Chlorination 
Hypochlorous 
acid 
H2O2 + Cl2             HOCl 
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OXIDATIVE STRESS 
 
Aerobic organisms use O2 to facilitate the synthesis of energy in the form of ATP 
mainly by two routes, glycolysis in cytosol and oxidative phosphorylation on the inner 
mitochondrial membrane (Kadenbach, 2003).  Oxidative phosphorylation comprises a 
respiratory chain consisting of four proton pumps or complexes and produces the 
majority of ATP required for the cell.  Aerobic organisms use O2 as the terminal electron 
acceptor for optimal energy release by mediating the transfer of single electrons (Nohl et 
al., 2004) through these complexes.  The electrons from reduced substrates are passed 
from complexes I and II of the electron transport chain through complexes III and IV to 
oxygen, forming water and causing protons to be pumped across the mitochondrial inner 
membrane (Brand et al., 2004).  As oxygen is predisposed for univalent reductions 
(Fridovich, 1999), electrons may leak from the respiratory chain and react inappropriately 
with oxygen to form superoxide radical (O2.-).  The activity of mitochondrial respiratory 
chain complexes, particularly complex I, have been shown to be reduced by the 
accumulation of O2.- (Yen et al., 1999; Yen et al., 1996).  Superoxide radical can be 
considered as the parent radical from which other oxygen radicals and non-radicals are 
derived (Nohl et al., 2004).  Apart from O2.-, other superoxide derived reactive radicals 
include oxygen radicals like hydroxyl radical and peroxyl radicals, and nonradical 
molecules like singlet oxygen and hydrogen peroxide (Oberley, 2001), and are 
collectively called reactive oxygen species (ROS).  A vast majority of cellular ROS, 
approximately 90% can be traced back to oxidative phosphorylation in the mitochondria 
(Balaban et al., 2005).  Initial observations suggested that up to 5% of the total molecular 
oxygen utilized by mammalian mitochondria was converted into ROS (Boveris and 
Chance, 1973), but more recent analysis estimates about 1-2% to be converted into O2.-
anion (Cadenas and Davies, 2000).  Superoxide and other secondary reactive oxygen 
species it generates (Brand et al., 2004) can damage proteins, lipids and DNA directly.  
To prevent the detrimental effects of ROS-induced injury, cells are equipped with an 
elaborate antioxidant defense system that is comprised of agents that catalytically remove 
ROS, agents that decrease ROS formation, proteins that protect biomolecules against 
13
oxidative damage by other mechanisms, the physical quenching of ROS, the replacement 
of molecules susceptible to oxidative damage by molecules resistant to it and the 
sacrificial agents that are preferentially oxidized by ROS to preserve more important 
biomolecules (Halliwell and Gutteridge, 2007).  ROS can also be generated by other 
systems existing in endoplasmic reticulum, peroxisomes, intracellular membrane-
associated oxidases, plasma membrane-associated oxidases and auto-oxidation of small 
molecules like dopamine, epinephrine, flavins and epinephrine (Thannickal and Fanburg, 
2000).  Any disturbance in the pro-oxidant and anti-oxidant balance in favor of the 
former is defined as oxidative stress (Sies, 1985).  Brain as a result of consumption of an 
inordinate fraction (20%) of the total oxygen consumption for its relatively small weight 
(2%), its abundance of easily peroxidizable lipid content (Floyd, 1999), and the relative 
paucity of antioxidant enzymes compared to other tissues (Markesbery, 1997), is 
especially vulnerable to oxidative stress.   
 
ANTIOXIDANT SYSTEMS  
 
There are three major types of primary interacting (Chow et al., 2002) 
intracellular antioxidant enzymes in mammalian cells that can remove ROS: superoxide 
dismutase (SOD), catalase (CAT), peroxidase, of which glutathione peroxidase (GPx) 
(Oberley, 2001) and peroxiredoxins (Prx) (Halliwell and Gutteridge, 2007) are the most 
prominent. The SODs catalyze the dismutation of O2.- into hydrogen peroxide (H2O2) and 
molecular oxygen.  Hydrogen peroxide is further detoxified by CAT, GPx (Halliwell and 
Gutteridge, 1989) and Prx to water.  Thus, two reactive species - O2.- and H2O2 are 
converted to water (Oberley, 2001) and molecular oxygen. Among the antioxidant 
systems, SOD is considered the first line of defense against oxidative stress (Halliwell, 
1999; Ho et al., 1998).  Three distinct SODs are found in human cells: a homodimeric 
cytosolic copper zinc SOD (CuZnSOD) (McCord and Fridovich, 1969), a extra-cellular 
homotetrameric glycolsylated CuZnSOD (Marklund, 1982) and mitochondrial matrix 
homotetrameric manganese SOD (MnSOD) (Figure 1.2) (Weisiger and Fridovich, 1973).   
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Figure 1.2  Scheme for production of superoxide and its detoxification
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MANGANESE SUPEROXIDE DISMUTASE (MnSOD) 
 
MnSOD is a critical antioxidant enzyme in aerobic organisms because under 
physiological conditions superoxide is mainly generated on the matrix side of the inner 
mitochondrial membrane where MnSOD is located (Balzan et al., 1999) in high 
concentrations (Van Remmen et al., 1999).  Thus MnSOD can protect mitochondria from 
oxidative damage (Van Remmen et al., 1999).    
MnSOD from different organisms are homologous and has a manganese ion in the 
active site.  While Human MnSOD is a homotetramer with identical 24-kd subunits 
(Matsuda et al., 1990), E.coli MnSOD is a dimer (Beyer et al., 1991).  It is a single-copy 
gene consisting of five exons separated by four introns (Wan et al., 1994).  The human, 
bovine and mouse MnSOD cDNAs share more than 90% similarity (Meyrick and 
Magnuson, 1994).  The gene is characterized by lack of a TATA or CAAT box and the 
presence of a GC-rich region containing SP-1 binding sites (Wan et al., 1994).  The 
mature protein is strictly a mitochondrial enzyme compartmentalized in the mitochondrial 
matrix, although it is encoded by the nuclear sod2 gene, localized in chromosome 6q25 
(Matsuda et al., 1990).  Studies performed by us and others have shown that the 
imbalance between antioxidants and oxidants leads to various pathological conditions 
which can be effectively prevented or alleviated by increased MnSOD (Keller et al., 
1998; St Clair et al., 1991; Yen et al., 1996).  The over-all importance of this enzyme is 
evident from transgenic animal studies, wherein MnSOD “knock-out” usually dies within 
10 days after birth, with cardiac abnormalities, fat accumulation in liver and skeletal 
muscle (Lebovitz et al., 1996; Li et al., 1995), and metabolic acidosis (Lebovitz et al., 
1996) with animals surviving longer than 10 days soon succumbing to severe anemia and 
neurodegeneration (Melov et al., 1998).  It has been demonstrated that MnSOD 
heterozygous knock-out mice show altered mitochondrial function as illustrated by 
decreased respiration by complex I and an increase in the sensitivity of the permeability 
transition pore induction (Van Remmen et al., 2001), while overexpression of MnSOD 
protected complex I inactivation (Yen et al., 1999).  Thus, mitochondrial function and 
oxidative phosphorylation, necessary machinery for the ATP production in the cell are 
likely to be influenced by MnSOD function.  Further, recent studies suggest that MnSOD 
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plays a protective role during AD development.  For example, MnSOD deficiency 
increased β-amyloid levels and amyloid plaque burden, and accelerated the onset of 
behavioral alteration in APP transgenic mice (Esposito et al., 2006; Li et al., 2004)  
 
NITRATION OF MnSOD AND NITROTYROSINE IN AD 
 
Post-translation modification like nitration of tyrosine residues present on the 
subunits of MnSOD can compromise its activity (Ischiropoulos et al., 1992).  Of the nine 
tyrosine residues in each subunit of the homotetrameric protein MnSOD, tyrosines 34, 45 
and 193 have been shown to be nitrated, with nitration of tyrosine residue 34 causing 
inactivation of MnSOD (MacMillan-Crow et al., 1998).  Nitration of  biological 
macromolecules can be mediated by nitric oxide, nitrogen dioxide, nitrous acid, 
hypochlorous acid, nitrated aliphatic reactive intermediates and peroxynitrite 
(Ischiropoulos, 1998).  But only peroxynitrite has been demonstrated to nitrate tyrosine 
34 of MnSOD leading to its inactivation (MacMillan-Crow et al., 1998; Yamakura et al., 
1998).  Residues 45 and 193 are prone for nitration because of their location with 
proximal glutamate residues.  The apparent ability of glutamate residues to direct 
peroxynitrite-mediated nitration to specific tyrosine residues is implicated in this situation 
(MacMillan-Crow et al., 1998).  Even though tyrosine 34 has no proximal glutamate, it is 
the most susceptible residue for nitration.  This is probably because of its positioning 
closest to the active site, only 5 Å from the manganese ion.  The attraction of 
peroxynitrite to the active site, by the basic residues in the channel entrance, and its 
reaction with manganese ion leading to the formation of nitrating species makes tyrosine 
34 more prone for nitration, and thereby inactivating MnSOD (Quijano et al., 2001).  The 
experiments carried out with E. coli MnSOD, in the absence of manganese ion 
demonstrated a reduced nitration on treatment with peroxynitrite suggesting that the 
metal center could be involved in nitration possibly by the formation of nitrating species 
like nitronium ion or an oxo-manganese complex plus nitrogen dioxide (Quijano et al., 
2001).   
NT is a stable adduct involving a carbon – nitrogen bond that is difficult to 
remove chemically.  The routes of removing NT in vivo are not yet known, but 
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proteolysis is likely to a major route.  NT can be excreted in human urine as an amino 
acid and as decarboxylated and deaminated products (Beckman, 1996).  Tyrosine can be 
nitrated by several pathways in vitro; it is a common modification made by protein 
chemists to probe the function of tyrosine residues (Beckman, 1996).  
In AD, the levels of 3-NT has been shown to be consistently elevated in 
hippocampus, neocortical regions and cerebrospinal fluid of AD patients (Hensley et al., 
1998).  3-NT levels correlates positively with decreased cognitive functions (Tohgi et al., 
1999).  The formation of 3-NT by addition of a nitro group onto the tyrosine phenols is a 
post-translational modification with potentially significant biological implications 
(Beckman, 1996; Ischiropoulos, 1998; Smith et al., 1996). The functional consequence of 
3-NT formation may be causally linked to pathogenesis of various diseases through 
interference of enzyme function, structural protein assembly or modulation of signaling 
cascades (Berlett et al., 1998; Estevez et al., 1999; Go et al., 1999; MacMillan-Crow et 
al., 1998).  Although there is no consensus either about the activity level of MnSOD or 
the nitration status of MnSOD in AD, there have been reports of reduction of SOD 
activity in AD frontal cortex, hippocampus and cerebellum (Marklund et al., 1985).   
Extensive data exist to implicate peroxynitrite as a consistent mediator of 3-NT 
formation (MacMillan-Crow et al., 1996; Smith et al., 1996; Yamakura et al., 1998; 
Yamamoto et al., 2002). Of relevance to AD is the finding of increased peroxynitrite 
production in the synaptosomes exposed to Aβ (Keller et al., 1997).  Although one of the 
major oxidative modifications of proteins resulting from peroxynitrite is carbonyl 
formation from side-chain and peptide-bond cleavage, perhaps the best known property 
of ONOO- is its ability to nitrate free tyrosine and tyrosine residues in proteins 
(Ischiropoulos et al., 1992; Souza et al., 1999).  Importantly, MnSOD, has been shown to 
be nitrated and inactivated in chronic rejection of human renal allograft, which was 
proposed to be a general mechanism for the amplification of ONOO- mediated oxidative 
damage (MacMillan-Crow et al., 1996).  Overall,  the presence of 3-NT has been 
suggested to be a signature of peroxynitrite involvement (Smith et al., 1997).   
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PEROXYNITRITE 
 
Peroxynitrite has been the subject of intense investigation by researchers loyal to 
inorganic peroxide chemistry, radiation, and photochemistry.  Since 1990, peroxynitrite 
caught the attention of a larger scientific community because of its implications to 
biological systems (Beckman et al., 1990).  Peroxynitrite is a powerful oxidant and 
cytotoxic agent formed by the reaction between the free radicals nitric oxide ( 
. 
NO) and 
superoxide (O2.-) at rates approaching diffusion limit – 6.7 x 109 M-1s-1 (Beckman, 1996; 
Huie and Padmaja, 1993).  As superoxide is short lived and has restricted diffusion across 
membranes, peroxynitrite formation has to be spatially associated with the sources of 
superoxide (plasma membrane NAD(P)H oxidases or the mitochondrial respiratory 
complexes).  Nitric oxide produced from cytosolic NOS can diffuse into mitochondria.  
This capacity of nitric oxide along with the reports on the presence of nitric oxide 
synthase inside mitochondria (Tatoyan and Giulivi, 1998), make the intramitochondrial 
formation of peroxynitrite possible. Targets of peroxynitrite inside mitochondria 
including MnSOD has been observed (MacMillan-Crow et al., 1996).   
In AD brain, nitric oxide can be produced due to activation of inducible nitric 
oxide synthase (iNOS) by Aβ surrounding the amyloid plaques (Combs et al., 2001) or 
from neuronal nitric oxide synthase (nNOS) induced by Aβ (Stepanichev et al., 2008).  
The rate of production of peroxynitrite in vivo in specific compartments has been 
estimated to be as high as 50 – 100 μM per minute (Szabo et al., 2007).  The short half 
life of peroxynitrite (~ 10 ms) is compensated for by its ability to cross cell membranes 
with a permeability coefficient comparable to water (Marla et al., 1997).  Thus it could 
influence surrounding targets cells within one to two cell diameters (~ 5-20 μm).  
Externally added ONOO- has been shown to diffuse lipid bilayers passively (Denicola et 
al., 1998) over distances of 1 - 10 μm (Radi, 1998).   
Peroxynitrite itself is not a free radical because the two unpaired electrons on 
superoxide and nitric oxide have combined to form a new bond.  Peroxynitrite is a isomer 
of nitrate (Beckman, 1996).  It is relatively stable in alkaline solution and can be stored in 
millimolar concentrations at -80oC for months (Beckman et al., 1994).  The biochemistry 
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and the reaction of peroxynitrite and/or peroxynitrite-derived with their targets is 
illustrated in the Figure 1.3. 
Many biomolecules are oxidized and/or nitrated by peroxynitrite/peroxynitrite – 
derived species, including tyrosine residues, thiols, DNA and unsaturated fatty-acid 
containing phospholipids (Szabo et al., 2007).  3 – nitrotyrosine (3-NT), 3 , 3’ – 
dityrosine and 3, 4’ – dihydrophenylalanine are formed by nitration, dimerization and 
hydroxylation respectively, by the action of peroxynitrite on tyrosine residues (Radi, 
2004).  Apart from tyrosine, cysteine, methionine, phenylalanine are also oxidized 
(Beckman and Koppenol, 1996; Ischiropoulos and al-Mehdi, 1995).  Thiols can be 
oxidized by one – electron reactions by peroxynitrite-derived radicals (Quijano et al., 
1997).  In DNA, purine nucleotides are vulnerable to oxidation and adduct formation, 
with 8 – oxo and 8 – nitroguanine being two of the major products.  Peroxynitrite is also 
capable of causing deoxyribose oxidation and strand breaks (Szabo et al., 2007).  
Peroxynitrite-derived radicals react with lipids leading to peroxidation (Radi et al., 1991), 
and formation of nitrito-, nitro-, nitrosoperoxo- and/or nitrated lipid oxidation adducts 
(Szabo et al., 2007).     
 
ENERGY METABOLISM 
  
ATP is the universal currency for biological energy, and the predominant source 
of cellular energy is glucose.  Energy is required mainly for three purposes: (1) for the 
maintenance of body structure (2) for work activities (3) for thermogenesis (Kadenbach, 
2003).  ATP can be generated by oxidizing several metabolic fuels, but carbohydrates 
and fats are especially important.  ATP is generated from fatty acids after their 
conversion to acetyl CoA by beta – oxidation in the mitochondria.  Three metabolic 
pathways are involved in the production of ATP from fatty acids.  These are the beta – 
oxidation, Krebs cyle and the respiratory chain.  Like that from glucose, the acetyl CoA 
formed by beta – oxidation goes through Krebs cycle and respiratory chain to produce 
ATP.  In brain, the ATP produced from fatty acid is of little value as the activity of 
ketoacyl Co-A thiolase, a key enzyme involved in beta – oxidation is 125 times lower 
compared to other tissues (Yang et al., 1987).  So glucose is the obligatory energy source 
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Figure 1.3  Biochemistry of Peroxynitrite: reaction and fate, adopted from Szabo et al., 2007
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for the brain.  The ATP from glucose is derived through three major pathways producing 
carbon dioxide and water as the end products.  In aerobic organisms, glucose is 
metabolized through glycolysis occurring in the cytoplasm, Kreb’s cycle and electron 
transport chain in the mitochondria to produce energy in the form ATP.   
 First process in the utilization of glucose for energy production is glycolysis.  In 
this process, one molecule of glucose is broken down in a series of ten enzymatically 
catalyzed reactions to two molecules of pyruvate.  In the priming phase of glycolysis, two 
ATPs are utilized to produce fructose 1,6-bisphosphate, followed by the energy 
producing phase, where fructose 1,6-bisphosphate is converted stepwise to pyruvate with 
the production four molecules of ATP and two molecules of NADH.  As two ATP 
molecules were consumed in the priming phase, there is a net gain of two ATP 
molecules.  The overall reaction can be depicted as follows 
Glucose + 2 Pi + 2 ADP + 2 NAD+ → 2 Pyruvate + 2 ATP + 2 NADH + 2 H+ + 2 H2O 
 After the glycolysis takes place in the cell's cytoplasm, the pyruvate molecules 
travel into the interior of the mitochondrion.  Carbon dioxide is enzymatically removed 
from each three-carbon pyruvate molecule to form acetic acid.  The enzyme then 
combines the acetic acid with an enzyme, coenzyme A, to produce acetyl coenzyme A, 
also known as acetyl CoA.  Once acetyl CoA is formed, the Krebs cycle begins.  This 
important step of converting pyruvate to acetyl CoA is catalyzed by the enzyme pyruvate 
dehydrogenase (PDH).  The Krebs cycle consists of eight steps, catalyzed by various 
enzymes, resulting in the production of 2 ATP molecules, 6 NADH molecules, 2 FADH2 
and 4 carbon dioxide molecules.  The overall reaction is as follows 
2 Acetyl CoA + 4 H2O + 6 NAD + 2 FAD → 6 NADH + 2 FADH2 + 4 CO2 + 2 ATP 
 The electron transport chain comprises of three proton pumps namely, NADH 
dehydrogenase or complex I, cytochrome c reductase or cytochrome bc1 complex or 
complex III and cytochrome c oxidase or complex IV; and an enzyme complex not 
pumping protons – succinate deydrogenase or complex II (Kadenbach, 2003).  In addition 
to these complexes, two mobile carriers are also involved: ubiquinone, and cytochrome c.  
Other key components in this process are NADH/FADH2 and the electrons from them, 
hydrogen ions, molecular oxygen, water, and ADP and Pi, which combine to form ATP.  
Electron transport chain transfers electrons from NADH and FADH2 to complexes I and 
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II respectively through complexes III and IV to oxygen, forming water and causing 
protons to be pumped across the mitochondrial inner membrane (Brand et al., 2004).   
At the start of the electron transport chain, two electrons are passed from NADH 
into the NADH dehydrogenase complex.  Coupled with this transfer is the pumping of 
one hydrogen ion for each electron.  Next, the two electrons are transferred to 
ubiquinone.  Ubiquinone is called a mobile transfer molecule because it moves the 
electrons to the cytochrome bc1 complex.  Each electron is then passed from the 
cytochrome bc1 complex to cytochrome c.  Cytochrome c accepts each electron one at a 
time. One hydrogen ion is pumped through the complex as each electron is transferred. 
The next major step occurs in the cytochrome oxidase complex.  This step requires four 
electrons. These four electrons interact with a molecular oxygen molecule and eight 
hydrogen ions. The four electrons, four of the hydrogen ions, and the molecular oxygen, 
are used to form two water molecules. The other four hydrogen ions are pumped across 
the membrane.  The energy from the transfer of electrons along the chain transports 
protons across the membrane and creates an electrochemical gradient.  The potential 
energy in this gradient is used by ATP synthase to generate ATP from ADP and 
inorganic phosphate.  The final reaction of electron transport chain is as follows 
4 H+ + O2 + 4 e- → 2 H2O 
Total ATP produced from electron transport chain is 32, which is as outlined below 
1. Each NADH produced in Glycolysis is worth 2 ATP (2 x 2 = 4).  In actuality, 
NADH is worth 3 ATP, but it costs an ATP to transport the NADH into the 
mitochondria, so there is a net gain of 2 ATP for each NADH produced in 
glycolysis  
2. Each NADH produced in the conversion of pyruvate (2 NADH)  to acetyl CoA 
and Krebs Cycle ( 6 NADH) is worth 3 ATP so 8 NADH x 3 ATP = 24 ATP  
3. Each FADH2 is worth 2 ATP so 2 FADH2 x 2 ATP = 4 ATP 
4. 4 from NADH of glycoloysis + 24 from NADH of Kreb’s cycle + 4 FADH2 of 
Kreb’s cycle = 32 ATP 
Over all, if we add the 4 ATPs produced from glycolysis and Kreb’s cycle (2 each), a 
total of 36 ATPs are produced from a single molecule of glucose.   
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Under physiological conditions, the amount of ATP supplied by glycolytic pathway is 
meager.  But in many tumors having impaired mitochondrial function and thereby 
reduced ATP supply from oxidative phosphorylation pathway, there can be up regulation 
(faster) of glycolytic capacity.  It has been proposed that glycolysis can proceed 100 
times faster than respiration, which in turn yield 18-fold more ATP (Bartrons and Caro, 
2007), thus acting as a compensatory response for the impaired mitochondrial function.  
 
ALTERED METABOLISM IN AD 
 
As glucose is the obligatory energy source for the brain, its utilization has been 
increasingly investigated in AD.  AD patients exhibit reduced glucose metabolism in 
parietal cortex and temporal gyri when studied longitudinally for one year (Hirono et al., 
2004). Specifically, the reduced activity of pyruvate dehydrogenase complex was 
observed as early as 1980 in the cerebral cortex of AD patients (Perry et al., 1980).  The 
enzymes involved in tricarboxylic cycle also show altered activity in prefrontal cortex of 
AD patients (Bubber et al., 2005).  In addition to AD patients, transgenic mice Tg2576 
exhibiting Alzheimer plaque pathology also show reduced activity of phospho fructo 
kinase (PFK) (Bigl et al., 2003).  Further, Aβ treated hippocampal neurons have showed 
significant decrease in glucose uptake (Prapong et al., 2002).  Further, report on nitration 
of alpha-enolase, glyceraldehyde-3-phosphate dehydrogenase, ATP synthase alpha chain, 
voltage-dependent anion channel – 1 and carbonic anhydrase, enzymes involved in 
energy production, in AD brain hippocampus (Sultana et al., 2006) have opened up a new 
area of AD research.  This alteration of the enzymes involved in energy production is 
consistent with that of AD patients having reduced activity of mitochondrial electron 
chain components, particularly cytochrome oxidase (Kish et al., 1999; Maurer et al., 
2000).  These findings suggest an environment of altered energy production.  Decreased 
function of electron transport chain components could cause diversion of electrons from 
their normal pathway into reaction with molecular oxygen in the neocortex and 
hippocampus of AD, resulting in increased superoxide (O2.-) formation, exacerbating the 
oxidative stress (Markesbery, 1997).   Thus it is possible that nitration of proteins 
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involved in energy production and/or protection of mitochondrial function, may be 
responsible for the observed metabolic impairment encountered in AD. 
 
RESEARCH OBJECTIVES 
 
Although, it is documented that, overpression of MnSOD protects against Aβ 
induced neurotoxicity, there is no consensus about the activity of MnSOD in AD brain.  
In this regard, this dissertation addresses the following hypotheses: 
 
1. MnSOD is nitrated and inactivated in association with Aβ deposition.   
 
To address this hypothesis, in chapter two, a homozygous knock-in APPNLh/NLh x PS-
1P264L/P264L mouse that simulates a natural progression of Aβ plaque pathology observed 
in AD (Reaume et al., 1996) was used to investigate the correlation between Aβ plaque 
deposition and nitration of MnSOD.  An increased and accelerated deposition of Aβ and 
increased levels of Aβ 1-40/ 1-42 along with increased nitration and subsequent 
inactivation of MnSOD in association with age, was observed in APPNLh/NLh x PS-
1P264L/P264L mice.  This change was also associated with impaired mitochondrial 
respiration. 
 
2. Nitrative inactivation of MnSOD plays an important role in the impairment 
of mitochondrial respiration resulting in alteration of energy metabolism.    
 
This hypothesis is addressed in chapter three, where the SH-SY5Y neuroblastoma cell 
line was treated with peroxynitrite to nitrate MnSOD.  MnSOD was nitrated upon 
peroxynitrite treatment with an associated decrease in activity.  An impairment of 
mitochondrial respiratory function was also observed.  Inactivation of MnSOD was an 
early event in peroxynitrite-induced impairment of mitochondrial function.  
Mitochondrial dysfunction was ameliorated by SOD mimetic and reproduced by MnSOD 
deficiency.  The impairment of mitochondrial respiratory function was compensated by 
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increased glycolytic activity, which was prevented by SOD mimetic and enhanced by 
MnSOD deficiency.  
 
1. The impairment of mitochondrial respiration observed in APP/PS-1 mice 
was also associated with an increase in glycolytic activity. 
 
This is addressed in chapter four, where we demonstrate increase in lactate levels, 
an indicator of enhanced glycolytic activity and increase in activity of lactate 
dehydrogenase in homozygous knock-in APPNLh/NLh x PS-1P264L/P264L mouse.  This was 
also associated with decrease in pyruvate dehydrogenase activity which can exaggerate 
the impaired mitochondrial function.   
These results demonstrate a critical role for MnSOD in maintaining mitochondrial 
respiratory function and reveal the role of glycolysis in sustaining cellular energy 
requirements under pathological conditions associated with MnSOD deficiency.  
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CHAPTER TWO 
 
β - AMYLOID MEDIATED NITRATION OF MANGANESE SUPEROXIDE 
DISMUTASE 
Implication for Oxidative Stress in a APPNLh/NLh X PS-1P264L/P264L Double Knock-In 
Mouse Model of Alzheimer’s Disease 
 
ABSTRACT 
 
Alzheimer’s disease is a multifactorial, progressive, age-related neurodegenerative 
disease.  In familial Alzheimer’s disease, Aβ is excessively produced and deposited 
because of mutations in the amyloid precursor protein, presenilin - 1, and presenilin - 2 
genes.  Here, we generated a double homozygous knock-in mouse model that 
incorporates the Swedish familial Alzheimer’s disease mutations and converts mouse Aβ 
to the human sequence in amyloid precursor protein and had the P264L familial 
Alzheimer’s disease mutation in presenilin - 1.  We observed Aβ deposition in double 
knock-in mice beginning at 6 months as well as an increase in the levels of insoluble Aβ1-
40/1-42. Brain homogenates from 3-, 6-, 9-, 12-, and 14-month-old mice showed that 
protein levels of manganese superoxide dismutase (MnSOD) were unchanged in the 
double knock-in mice compared to controls.  Genotype-associated increases in 
nitrotyrosine levels were observed. Protein immunoprecipitation revealed MnSOD as a 
target of this nitration.  Although the levels of MnSOD protein did not change, MnSOD 
activity and mitochondrial respiration decreased in knock-in mice, suggesting 
compromised mitochondrial function.  The compromised activity of MnSOD, a primary 
antioxidant enzyme protecting mitochondria, may explain mitochondrial dysfunction and 
provide the missing link between Aβ-induced oxidative stress and Alzheimer’s disease. 
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INTRODUCTION 
 
Alzheimer’s disease (AD) is a multifactorial, progressive age-related 
neurodegenerative disease that affects more than four million persons in the United States 
(Evans et al., 1989).  The pathological hallmarks of AD are extracellular Aβ deposits, 
neurofibrillary tangles, synaptic loss, and neuronal degeneration.  Aβ plaques are 
composed of 40- and 42-mer peptides (Aβ1-40 and Aβ1-42) that are proteolytically 
produced from amyloid precursor protein (APP) (Iwatsubo et al., 1994).  Three genes, 
presenilin 1 (PS-1), PS-2, and APP are causatively linked with the pathogenesis of early 
onset familial AD (FAD).  The findings that Aβ is central to the pathogenesis of AD 
(Selkoe, 2001) and that the AD brain is under significant oxidative stress were united into 
a comprehensive model for neurodegeneration in the brain in AD based on Aβ-associated 
free radical generation (Butterfield and Lauderback, 2002).  The brain in AD has marked 
oxidative damage as manifested by increased protein oxidation, lipid peroxidation, free 
radical formation (Butterfield and Lauderback, 2002), 3-nitrotyrosine (3-NT) levels 
(Castegna et al., 2003; Smith et al., 1997), advanced glycation end products, and 
DNA/RNA oxidation products (Mecocci et al., 1994; Nunomura et al., 1999). 
Manganese superoxide dismutase (MnSOD) is a homotetramer consisting of 
identical 24-kd subunits.  The translated precursor in cytosol contains an N-terminal 24-
amino acid sequence signaling mitochondrial compartmentalization.  The mature protein 
protects the cells against cytotoxic O2–..  The importance of this enzyme is evident from 
MnSOD knockout mice that suffer from a defect of mitochondrial iron-sulfur centers, a 
modification proving lethal to newborns (Lebovitz et al., 1996; Li et al., 1995).  Activity 
of this antioxidant enzyme declines in the aging process (Wei and Lee, 2002).  Because 
the AD brain is under intense oxidative stress, any dysfunction of MnSOD may lead to 
progression of the disease.  
Peroxynitrite anion (ONOO–) is a potent biological oxidant that has been 
implicated in diverse forms of free radical-induced tissue injury (Wiseman and Halliwell, 
1996).  Peroxynitrite is produced by the reaction of O2–. and .NO, and this peroxynitrite 
can compromise the functional and/or structural integrity of target proteins (Beckman, 
1996).  Increased levels of nitrotyrosine (Smith et al., 1997) and 4-hydroxynonenal 
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(Montine et al., 1997) are associated with degenerating neurons in AD, suggesting 
pathogenic roles of peroxynitrite and membrane lipid peroxidation in this disease.  
Mutations in the APP gene and PS - 1 gene lead to increased levels of Aβ, which 
appear to contribute to the disease process. One study demonstrated altered levels of Aβ1-
40 and Aβ1-42 distinguish AD from normal aging (Games et al., 1995).  Recently, several 
transgenic animals have been shown to have increased Aβ peptide deposition and some of 
the pathological characteristics similar to AD patients (Wang et al., 1999).  Crossing 
APP-Tg mutant mice and PS-1-Tg mutant mice resulted in increased Aβ production and 
accelerated amyloid deposition in the brains of these animals (Borchelt et al., 1997).  
However, increased Aβ levels in these models may, in part, be attributable to an increase 
in copy number of the transgene.  
The aim of this study was to use a mouse model that resembles the natural 
progression of Aβ pathology similar to that observed in AD patients and to gain insight 
into potential causes of the mitochondrial alterations that occur during the progression of 
AD.  The model that we used is a homozygous knock-in APPNLh/NLh X PS-1P264L/P264L 
(APP/PS-1) (Reaume et al., 1996; Siman et al., 2000).  The results presented here 
demonstrate that these mice have an age-dependent accumulation of Aβ in the brain, 
consistent with an increase in both Aβ1-40 and Aβ1-42 and an accelerated decline in 
mitochondrial function associated with a decrease in activity of MnSOD because of 
nitration. These results suggest a novel Aβ-mediated nitrative inactivation of MnSOD and 
inhibition of mitochondrial function in AD.  
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MATERIALS AND METHODS 
 
Mutant Mouse Lines 
 
APPNLh/NLh X PS-1P264L/P264L mutant mice were generated using the Cre-lox 
knock-in technology (Reaume et al., 1996; Siman et al., 2000).  The APP strategy 
introduced the Swedish FADK670N/M671L mutations and changed the mouse sequence 
for Aβ to be identical to the human sequence (NLh).  These mice demonstrate proper 
cleavage of the APP protein to generate the Aβ peptide.  The PS-1 mutation targeted 
codons 264 and 265 of the mouse PS - 1 gene to introduce the proline to leucine (P264L) 
mutation.  When PS - 1 mutant mice (P264L) are crossed with the mutant APP mice 
(NLh), the mutations are driven by the endogenous promoters of the APP and PS - 1 
genes, and expression is limited to the replacement of these two endogenous genes and 
not by the expression of multiple transgenes.  
 
Genotyping of Mice 
 
APP/PS-1 mice were maintained on a CD-1/129 background. Wild-type (WT) 
mice were obtained from heterozygous APP/PS-1 matings and maintained as a separate 
line for use as controls.  The APP/PS-1 mutant mice were monitored for maintenance of 
the knock-in gene by PCR analysis of tail snip DNA (Reaume et al., 1996).  The APP 
NLh mutation was screened with primers spanning the loxp sequence in intron 15 of the 
targeted locus (5'-CACACCAAGAAGTACAATAGAGGG-3' and 5'-
CCTGGGTTGTAGGGACTGTACTTG-3') (Invitrogen, Carlsbad, CA).  WT mice 
showed a single band at 214 bp, whereas the homozygous mutant mice had a single band 
at 298 bp. The PS - 1 P264L mutation was identified using primers spanning exon 8 (5'-
CCCGTGGAGGTCAGAAGTCAG-3' and 5'-TTACGGGTTGAGCCATGAATG-3') 
(Siman et al., 2000) (Invitrogen).  WT mice showed a single band at 142 bp, whereas the 
homozygous PS - 1 knock-in mutant mice showed a single band at 219 bp.  The mice 
used in all experiments were either WT or homozygous for APP/PS-1 mutation.  
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Immunocytochemistry for Aβ 
 
To determine the deposition of Aβ in APP/PS-1 mice, one brain hemisphere from 
3-, 6-, 9-, 12-, and 14-month-old mice was fixed in 4% formaldehyde, processed in the 
standard manner, embedded in paraffin, and sectioned at 10-µm thickness.  The sections 
were deparaffinized, hydrated, and immersed in 88% formic acid for 3 minutes and 
washed in distilled water. After blocking with 15% filtered horse serum in automation 
buffer (Biomeda Corp., Foster City, CA) for 1 hour at room temperature, the sections 
were immunostained with 10D-5 monoclonal antibody (1:100) (NCL-B-amyloid) and a 
biotinylated anti-mouse IgG secondary antibody (Vector Laboratories, Burlingame, CA).  
The sections were developed using an ABC reagent kit (Vector Laboratories) and 
counterstained with hematoxylin.  
 
Tissue Preparation for Aβ Enzyme-Linked Immunosorbent Assay (ELISA) 
 
Cerebral cortices were serially extracted with Tris-buffered saline, pH 7.4, 
followed by RIPA buffer [0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate 
(SDS), 1% Nonidet P-40, and 5 mmol/L ethylenediaminetetraacetic acid in Tris-buffered 
saline] and finally in 70% formic acid. Protease inhibitor cocktail (pepstatin A, leupeptin, 
TPCK, TLCK, soybean trypsin inhibitor, 1 µg/ml of each in 5 mmol/L 
ethylenediaminetetraacetic acid) was added during Tris-buffered saline and RIPA 
extraction.  To measure the levels of Aβ1-40 and Aβ1-42, the supernatant obtained from 
the SDS extraction step was analyzed by ELISA.  
 
Sandwich ELISA to Determine the Levels of Insoluble Brain Aβ1-40 and Aβ1-42 
 
The sandwich ELISA used here was performed as described previously 
(Skovronsky et al., 1998; Suzuki et al., 1994; Turner et al., 1996), and the absorbencies 
falling within the standard curve for each assay were converted to pmol.  The sandwich 
ELISA consisted of a capture monoclonal antibody (mAb, BAN50) that was specific for 
the first 10 amino acids in Aβ and was used in conjunction with one of two different 
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detection antibodies, BA27 mAb specific for Aβ species ending at amino acid 40 or BC05 
mAb specific for Aβ species ending at position 42(43).  This ELISA had a detection limit 
of 3 to 6 fmol/well for Aβ1-40 and 1-42/43.  The mAbs BAN50, BA27, and BC05 were 
prepared as described previously, and each ELISA result was normalized for the dilution 
and tissue weight (pmol/µg wet tissue).  
 
Mitochondrial Isolation 
 
Mice were euthanized; brains (excluding cerebellum) of three mice from each age 
group were pooled, homogenized in 5 ml of ice-cold mitochondrial isolation buffer 
containing 0.225 mol/L D-mannitol, 0.075 mol/L sucrose, 20 mmol/L HEPES, 1 mmol/L 
EGTA, and 1% bovine serum albumin, pH 7.2, in a Dounce homogenizer with a glass 
pestle. The homogenized brains were then diluted with isolation buffer to a final volume 
of 10 ml, centrifuged at 1500 x g for 5 minutes.  The supernatant was kept on ice, and the 
pellet resuspended in 3 ml of isolation buffer, homogenized, and centrifuged at 1500 x g 
for 5 minutes.  The supernatants were combined and centrifuged at 13,500 x g for 10 
minutes. The brown mitochondrial pellets were resuspended in 100 µl of isolation buffer 
and kept on ice, and the protein concentration was determined by Bradford assay.  
 
Measurement of Mitochondrial Respiration 
 
Mitochondrial proteins were resuspended in buffer containing 0.25 mol/L sucrose, 
50 mmol/L HEPES, 2 mmol/L MgCl2, 1 mmol/L EGTA, 10 mmol/L KH2PO4, and 0.5% 
bovine serum albumin, pH 7.4. Oxygen consumption was measured using a Clark-type 
electrode oxygraph (Hansatech Inc., Norfolk, UK) with 10 mmol/L pyruvate and 5 
mmol/L malate as substrate in the absence of exogenous ADP (state 2 respiration) and 
after addition of 300 mmol/L ADP (state 3 respiration).  The ATPase inhibitor 
oligomycin (100 µg/ml) was then added to inhibit mitochondrial respiration.  In normally 
coupled mitochondria, the addition of oligomycin slows respiration to a rate similar to 
that of state 2, whereas in uncoupled mitochondria oligomycin inhibition is reduced. 
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Respiratory control ratio (RCR) was calculated as the ratios between state 3 and state 2 
respirations.  
 
Immunoprecipitation 
 
Isolated mitochondrial protein (200 µg) was resuspended in 200 µl of RIPA buffer 
(9.1 mmol/L Na2HPO4, 1.7 mmol/L NaH2PO4, 150 mmol/L NaCl, 0.5% sodium 
deoxycholate, 1% v/v Nonidet P-40, and 0.1% SDS, pH 7.2).  Polyclonal nitrotyrosine 
antibody (anti-rabbit, 2 µg/ml; Cayman Chemical, Ann Arbor, MI) was added and 
incubated overnight at 4°C. Protein A/G agarose (20 µl) (Santa Cruz Biotechnology, 
Santa Cruz, CA) was added to the mixture and incubated overnight.  Immunocomplexes 
were collected by centrifugation at 1000 x g for 5 minutes at 4°C, followed by washing 
with RIPA buffer, four times. Immunoprecipitated samples were recovered by 
resuspending in 2X sample loading buffer, immediately fractionated by reducing 
SDS/polyacrylamide gel electrophoresis (PAGE), and analyzed by Western blot.  
 
Western Blot Analysis 
 
Equal amounts of brain homogenated proteins were resuspended in 2X sample 
loading buffer and separated on 12.5% SDS-PAGE.  After separation by SDS/PAGE 
proteins were transferred electrophoretically to nitrocellulose membranes (Schleicher & 
Schuell, Dassell, Germany) and blocked with 5% nonfat dried milk in 50 mmol/L Tris, 
pH 7.9, 150 mmol/L NaCl, and 0.05% (v/v) Tween-20. After blocking, the blots were 
incubated overnight at 4°C with appropriate primary antibody (rabbit, anti-MnSOD IgG, 
dilution 1:10,000; Upstate Technology, Lake Placid, NY), followed by incubation with 
horseradish peroxidase-conjugated anti-rabbit secondary antibody. Probed membranes 
were washed three times, and immunoreactive proteins were detected using enhanced 
chemiluminescence (Amersham Corp., Piscataway, NJ).  
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MnSOD Activity Assay 
 
SOD activity in the homogenized brain sample was measured by the nitro blue 
tetrazolium (NBT)-bathocuproine sulfonate reduction inhibition method (Spitz and 
Oberley, 1989).  This is an assay based on the competition reaction between SOD and the 
indicator molecule NBT.  When increasing amounts of protein (containing SOD activity) 
were added to the system, the rate of NBT reduction was progressively inhibited. 
Potassium cyanide at 5 mmol/L was used to inhibit Cu/ZnSOD and thus measured only 
MnSOD activity.  The assay mixture also contained catalase to remove H2O2 and 
diethylenetriaminepentaacetic acid to chelate metal ions capable of redox cycling and 
interfering with the assay system.  One unit of SOD activity was defined as the amount of 
SOD protein that caused a 50% reduction in the background rate of NBT reduction.  
 
Statistical Analysis 
 
Statistical significance was analyzed by two-way analysis of variance, followed 
by Newman-Keuls multiple comparison test when applicable.  The experiments were 
repeated at least three times, and the graphs were drawn using Graph Pad Prism, version 
3.02. 
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RESULTS 
 
Aβ Deposition in APP/PS-1 Mice 
 
To determine the deposition of Aβ, we examined brain sections that were 
immunostained with 10D-5 antibody.  The brains from WT mice contained no plaques at 
any age.  The APP/PS-1 animals showed no deposition of Aβ at the age of 3 months 
(Figure 2.1A).  At the age of 6 months (Figure 2.1B), a few microscopic, scattered, small 
Aβ plaques were found in the frontal cortex.  By 9 months (Figure 2.1C) there were a few 
larger Aβ plaques and more scattered smaller Aβ deposits.  By 12 months (Figure 2.1D), 
Aβ deposition was more prominent in the neocortex and spread of plaques to the 
hippocampus occurred, with many larger confluent Aβ plaques and many small and 
moderate size plaques.  By 14 months, there were larger numbers of Aβ deposits and Aβ 
in small blood vessel walls in brain and leptomeninges (Figure 2.1E).  These results 
suggest that there was an age-related, regional dependence to Aβ deposition in APP/PS-1 
mice. 
 
Increased Levels of Aβ1-40 and 1-42 Fractions in APP/PS-1 Mice 
 
The accumulation of diverse species of Aβ peptides in amyloid plaques is a 
multistep process including the conversion of soluble Aβ into insoluble derivatives that 
assemble into amyloid fibrils and aggregate in extracellular deposits (Games et al., 1995).  
We examined whether the APP/PS-1 mice model showed an increase in levels of SDS-
soluble fractions of Aβ1-40 and 1-42 in cerebral cortical tissue.  APP/PS-1 mice exhibited 
a trend of age-related increase in the load of both species of Aβ (Figure 2.2A & B). 
 
Unchanged MnSOD Protein Levels in WT and APP/PS-1 Mice 
 
Expression of MnSOD is highly inducible by oxidative stress-inducing agents.  To 
determine whether increases in Aβ produced increases in MnSOD enzyme levels, 
Western blot analyses of brain homogenate from animals of different ages of both WT 
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Figure  2.1  Age-related Aβ deposition in the brains of APP/PS-1 mice
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Figure 2.1 Age-related Aβ deposition in the brains of APP/PS-1 mice. Sections of
frontal cortex from APP/PS-1 mice immunostained with 10D-5 antibody
for Aβ.
A. 3-month old animal showing no amyloid immunostaining in cortex.
B. 6-month old mouse showing rare small deposits of Aβ (arrows).
C. 9-month old mouse showing increased Aβ deposits.
D. 12- month old mouse demonstrating numerous variable size deposits of Aβ.
E. 14-month old mouse showing numerous diffuse Aβ deposits in cortex.
F. 14-month old mouse demonstrating many Aβ deposits in cortex in parenchymal and
leptomeningeal vessels (arrows). Original magnifications, ×100.
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Figure 2.2 Increased levels Aβ1-40 and 1-42 fractions in APP/PS-1 mice.
Aβ1-40 and Aβ1-42 levels were measured by ELISA from different groups (n = 5/group)
as described in Materials and Methods section. Both species of Aβ showed an increasing
trend in the levels associated with age (R2 = 0.8072 for Aβ1-40 and 0.702 for Aβ1-42).
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and APP/PS-1 mutant mice were performed.  The protein levels of MnSOD did not 
change when compared between genotypes or between different ages within a genotype 
(Figure 2.3A & B).  
 
Increased Nitration of MnSOD in APP/PS-1 Mice 
 
MnSOD is susceptible to peroxynitrite-induced inactivation (MacMillan-Crow et 
al., 1996).  To determine whether Aβ-induced oxidative stress was associated with 
nitration and inactivation of MnSOD, nitration of MnSOD was detected by Western blot 
analysis of SDS/PAGE-fractionated mitochondrial proteins, which had been 
immunoprecipitated using a polyclonal anti-nitrotyrosine antibody.  Immunodetection 
with polyclonal anti-MnSOD demonstrated detectable levels of nitrotyrosine in WT mice 
at all ages tested.  In contrast, the APP/PS-1 mice showed an increasing trend in the level 
of immunoreactive-nitrated MnSOD (Figure 2.4A & B), but the increase was not 
statistically significant at p < 0.05.  The increase was significant when compared between 
the two genotypes (p < 0.01). 
 
Decreased SOD Activity in APP/PS-1 Mice 
 
MnSOD catalyzes the dismutation of superoxide to hydrogen peroxide and 
molecular oxygen, and this conversion was used to estimate the activity of MnSOD.  The 
activity of MnSOD in APP/PS-1 mice was significantly decreased (p < 0.0001) when 
compared to the WT mice.  WT mice showed a significant (**p < 0.05) decrease in 
MnSOD activity at 12 and 14 months when compared to 3-month-old mice of their own 
genotype (Figure 2.4C).  There was also a significant decrease (*p < 0.05) in activity of 
MnSOD in APP/PS-1 mice when compared to their age-matched WT controls (Figure 
2.4C).  
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Figure 2.3 Unchanged MnSOD protein levels in WT and APP/PS-1 mice.
Representative (out of three) immunoblot (A) and densitometry analysis (B) showing the
levels of MnSOD. Protein (30 μg) extracted from brain specimens of APP/PS-1 knock-in
and wild type mice were run on a 12.5% SDS-polyacrylamide gel electrophoresis. Protein
levels of MnSOD did not show significant age and genotype associated alterations. β-actin
was used to normalize protein loading. WT – Wild type; HO – APP/PS-1.
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Figure 2.4 Increased nitration and decreased activity of MnSOD in APP/PS-1 mice
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Figure 2.4 Increased nitration and decreased activity of MnSOD in APP/PS-1 mice.
Immunoprecipitation of nitrotyrosine with MnSOD. Isolated mitochondrial
protein (200 µg) was precipitated with polyclonal nitrotyrosine antibody and
analyzed by Western blotting using MnSOD antibody
A. Nitrotyrosine coimmunoprecipitated with MnSOD showed that MnSOD is nitrated. WT –
Wild type; HO – APP/PS-1; Positive control – Brain homogenate + Peroxynitrite (2 µM),
provided by Dr. Timothy R. Miller, Graduate Center for Toxicology, University of
Kentucky, Lexington, Kentucky; Pellet – Pellet of the isolated mitochondrial protein (200
µg) precipitated with pre-immune IgG, analyzed by Western blotting using MnSOD
antibody; Supernatant of the isolated mitochondrial protein (200 µg) precipitated with
pre-immune serum, analyzed by Western blotting using MnSOD antibody
B. Densitometric analysis and subsequent statistical analysis by 2-way ANOVA showed
significant differences (*, p < 0.01) when compared between genotypes.
C. MnSOD activity in the brain specimen was measured by the nitroblue tetrazolium (NBT)-
bathocuproine sulfonate (BCS) reduction inhibition method.26 Statistical analysis by 2-
way ANOVA showed significant age- and genotype-dependent decreases (p < 0.0001) in
activity of MnSOD. APP/PS-1 mice, at all ages, showed significant decreases (*, p <
0.05) in MnSOD activity when compared with age-matched WT mice. WT mice at 12-
and 14-months showed significant decrease (**, p < 0.05) in MnSOD activity when
compared with 3-month old WT mice. Immunoprecipitation and MnSOD activity was
carried out in three sets of animals.
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Decreased Mitochondrial Respiration in APP/PS-1 Mice 
 
MnSOD is a primary antioxidant enzyme protecting mitochondria from oxidative 
injury.  To determine whether a reduction of MnSOD activity would affect mitochondrial 
respiratory function, oxygen consumption by isolated mitochondria was measured as an 
indicator of the mitochondrial respiration activity.  Pyruvate and malate were used as 
substrates to determine the function of brain mitochondria from WT and APP/PS-1 mice 
via complex I respiration.  The results showed that the RCR of mitochondria was 
significantly (*p < 0.01) decreased in 9- and 12-month-old APP/PS-1 mice when 
compared to age-matched WT mice and also when compared to 3-month-old mice of both 
genotypes (**p < 0.001) (Figure 2.5).  The results suggest that in APP/PS-1 mice there is 
inhibition of NAD-linked state 3 respiration rate, which is mediated through complex 1 of 
the mitochondrial electron transport chain.  WT mice showed a small decrease in 
mitochondrial respiration with age; however, it was not statistically significant. 
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Figure 2.5 Decline in mitochondrial respiration via complex I in APP/PS-1 mice.
Oxygen consumption was measured using a Clark-type electrode oxygraph. Respiratory
control ratio (RCR) was calculated as the ratios between state 3 and state 2 respirations.
APP/PS-1 mice at 9 and 12 months of age showed a significant decrease (*, p < 0.01) in
mitochondrial respiration when compared to its age-matched WT mice and a significant
decrease (**, p < 0.001) compared to 3-month old mice of both genotypes. Statistical
analysis – two-way ANOVA followed by Newman-Keuls multiple comparisons test.
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DISCUSSION 
 
Numerous reports have described attempts to recapitulate the hallmark 
pathologies of AD in the rodent brain by overexpression of human APP or APP 
fragments in transgenic models (Games et al., 1995; LaFerla et al., 1995; Lamb et al., 
1993); examples include, Tg2576 mice that overexpress human APP695 (Hsiao et al., 
1996) with Swedish FAD mutations, mice obtained by crossing Tg2576 mice and 
transgenic PS1-P264L mice (Holcomb et al., 1998; McGowan et al., 1999), and the 
crosses of other Swedish APP transgenic mice with transgenic FAD mutant PS-1 mice 
(Borchelt et al., 1997).  In this study, we used a double gene-targeted APPNLh/NLh/PS-
1P264L/P264L mouse model for amyloid deposition without the overexpression of APP 
(Flood et al., 2002). 
Humanization of the mouse Aβ gene sequence results in an approximate threefold 
increase in amyloidogenic processing of recombinant APP in rat hippocampal neurons 
infected with Semliki Forest virus expression constructs (De Strooper et al., 1995), and 
single mutant PS-1 allele was sufficient to elevate the concentration of Aβ42 in brain and 
speed the onset of amyloid deposition and reactive astrogliosis (Siman et al., 2000).  Our 
results using mice homozygous for APP/PS-1, which completely lack WT APP or PS-1 
and expressed both mutant FAD APP and PS-1 at natural levels, showed age-dependent 
increases in amyloid pathology (Figure 2) in accordance with the results obtained from 
APP 695SWE transgenic mice having PS-1 P264L knock-in mutation (Flood et al., 2002; 
Siman et al., 2000).  The observed accelerated Aβ deposition in APP/PS-1 mice also 
seems to have region dependence in relation to age, with deposition seen first in frontal 
cortex and later encompassing other cortical regions and hippocampus.  Thus, this 
humanized mouse model should serve as a useful model to study the Aβ-induced 
pathology in human AD.  
Measurement of Aβ1-40 and 1-42 showed that there was an increasing trend in 
both species in APP/PS-1 mice.  Our findings are in concordance with that of Wang and 
colleagues who demonstrated an increase in average levels of Aβ1-40 and Aβ1-42 in AD. 
Our finding of increased quantity of Aβ1-40 and Aβ1-42, is consistent with the possibility 
that Aβ1-42 serves as the initial seeding event for plaque formation and that increased 
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levels of Aβ1-40 play a role in growing plaques and may be mechanistically linked to the 
onset and progression of AD (Wang et al., 1999).  
The AD brain is under pronounced oxidative stress, as manifested by protein 
oxidation, lipid peroxidation, DNA and RNA oxidation, widespread peroxynitrite-
induced damage, advanced glycation end products, and altered antioxidant enzyme 
expression.  Via mechanisms that are inhibited by antioxidants such as vitamin E, Aβ 
causes brain cell protein oxidation, lipid peroxidation, and ROS formation, among other 
oxidative stress responses, suggesting that this peptide is a source of oxidative stress in 
the brain (Butterfield et al., 2001).  Other sources of oxidative stress in AD are likely, 
ranging from altered mitochondrial function, trace metal ion imbalances to binding of 
altered metal ion to biomolecules (Markesbery, 1997).  Our results indicating increased 
nitration of MnSOD protein signify an increase in oxidative stress in the brain of the 
APP/PS-1 mice and suggest a compromise in mitochondrial function of APP/PS-1 mice 
attributable to increased oxidative stress.  
The mitochondrion, a major subcellular source of ROS (Dugan et al., 1995) plays 
a pivotal role in apoptosis (Piantadosi and Zhang, 1996).  However, the mitochondrion is 
also a site of cellular protection against ROS that involves an elaborate antioxidant 
defense system, especially MnSOD. Our studies indicate that the expression pattern of 
MnSOD in APP/PS-1 mice remained unaltered in all age groups, but SOD activity in 
APP/PS-1 mice was significantly reduced when compared to age-matched WT mice, 
suggesting that the protein was inactivated. Our finding is in accordance with that 
reported by Macmillan-Crow and colleagues (MacMillan-Crow et al., 1996) in a chronic 
rejecting renal model.  The decreased activity of MnSOD is attributable to nitration of 
tyrosine residues (Smith et al., 1996; Smith et al., 1997) that occurs on the MnSOD 
protein.  Tyrosine nitration (3-nitrotyrosine, 3-NT) is an in vivo posttranslational protein 
modification with potentially significant biological implications (Beckman, 1996; 
Ischiropoulos, 1998) and has been detected in a number of human and animal models of 
disease (Kroemer et al., 1997).  3-NT is increased in the hippocampus and cerebral cortex 
of aged rats (Shin et al., 2002), the cerebrospinal fluid of aged humans (Tohgi et al., 
1999), and the subcortical white matter of aged monkeys (Sloane et al., 1999).  3-NT 
formation is the hallmark of reactive peroxynitrite (ONOO–), and this modification can 
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compromise the functional and/or structural integrity of target proteins (Smith et al., 
1996), especially MnSOD (Ischiropoulos et al., 1992).  After diffusing into mitochondria, 
.NO can inhibit oxygen consumption by complex IV. Inhibition by .NO is reversible; 
however, this process decreases electron transport and could potentially increase the 
concentration of O2–. (MacMillan-Crow et al., 1996).  MnSOD has a function to eliminate 
O2–. from the mitochondrial matrix space.  But, the concentration of .NO required to 
inhibit complex IV is sufficient to compete effectively with MnSOD for O2–. by a rapid 
reaction generating peroxynitrite, which can nitrate tyrosine residues and inactivate 
MnSOD to increase further the intramitochondrial level of O2–. (MacMillan-Crow et al., 
1996).  O2–. reacts with .NO faster than with MnSOD (Hsu et al., 1996); therefore, if 
mitochondria contain inactive MnSOD, this peroxynitrite can further nitrate MnSOD and 
inactivate MnSOD to increase the intramitochondrial level of superoxide.  Consequently 
this peroxynitrite-mediated amplification cycle would result in a progressive increase of 
mitochondrial levels of peroxynitrite, which can induce additional cytotoxic effects 
(MacMillan-Crow et al., 1996) including inactivation of complexes I and II in the 
mitochondrial respiratory chain (Cassina and Radi, 1996).  
Myeloperoxidase (MPO), one of the principle hemoproteins stored in the 
azurophilic granules of neutrophils and monocytes, is also a catalyst of nitrotyrosine 
formation via nitrite oxidation to the potent nitrating species nitrogen dioxide (.NO2) 
(Baldus et al., 2001).  It has been demonstrated in vascular tissues that MPO significantly 
contributes to nitrotyrosine formation in vivo (Baldus et al., 2002; Baldus et al., 2001).  
Further, it has been shown that MPO –/– animals have reduced nitrotyrosine 
immunoreactivity than WT mice (Baldus et al., 2002).  MPO is not only present in 
neutrophils and monocytes, but also in microglia.  Microglia are quiescent in normal 
brain but can become activated in response to neuronal damage or various other stimuli, 
including aggregated Aβ (El Khoury et al., 1998; Meda et al., 1995).  In AD, MPO has 
been shown to be co-localized around the Aβ plaques and also in microglia-macrophages 
that are present around the plaques.  It has also been shown that Aβ treatment of the 
mouse microglia cell line BV-2 resulted in strong induction of MPO mRNA expression 
(Reynolds et al., 1999).  From these observations and the fact that senile plaques are 
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surrounded by activated microglia, it can be cautiously speculated that MPO may also 
contribute to the nitration of MnSOD.  
Despite major advances in the study of nitration of proteins, the effect of nitration 
on protein turnover and the pathways that degrade the nitrated proteins have not been 
fully elucidated.  There are reports about faster degradation of proteins treated with 
peroxynitrite or a generator of nitric oxide and superoxide by 20S proteasome (Grune et 
al., 1998).  Consistent with this, Souza and colleagues (Souza et al., 2000) reported that a 
single nitrating event is sufficient to target proteins for degradation by the proteasome.  
Although protein nitration is generally viewed as an irreversible event, activities that 
appear to specifically repair nitrated proteins have been reported in human and rat tissues 
(Gow et al., 1996; Kamisaki et al., 1998).  Thus it tempting to speculate that nitration of 
MnSOD may be reversible.  In this regard, our APP/PS-1 mouse model is ideal for testing 
pharmacological intervention by mitochondrially targeted antioxidants such Mito-Q or 
Mito-Vit E.  
Mito-Q [mixture of mitoquinol-10-(6'-ubiquinolyl)de-cytriphenylphosphonium 
and mitoquinone-10-(6'-ubiquinonyl)decyltriphenylphosphonium] (Kelso et al., 2001) 
and MitoVit E [2-[2-(triphenylphosphonio)ethyl]-3,4-dihydro-2,5,7,8-tetra-methyl-2H-1-
benzopyran-6-ol bromide] have been found to destroy superoxide in the mitochondrial 
matrix (Echtay et al., 2002).  Mito-Q (Mito-Q10) has been shown to be an effective 
antioxidant against lipid peroxidation, peroxynitrite, and superoxide (James et al., 2005).  
Pretreatment with Mito-Q and Mito Vit-E have been shown to 1) significantly abrogate 
the lipid peroxide-induced 2'-7'-dichlorofluorescein fluorescence and protein oxidation in 
bovine aortic endothelial cells; 2) inhibit cytochrome c release, caspase-3 activation, and 
DNA fragmentation; 3) inhibit H2O2 and lipid peroxide-induced inactivation of complex I 
and aconitase, thus preventing the production of superoxide; 4) inhibit TfR 
overexpression and mitochondrial uptake of 55Fe, thereby inhibiting apoptosis; and 5) 
restore the mitochondrial membrane potential and proteasomal activity (Dhanasekaran et 
al., 2004).  Further, the pro-oxidant effect or superoxide production by Mito-Q10 was 
found to be insufficient to cause any damage but led to hydrogen peroxide production and 
nitric oxide consumption (James et al., 2005).  Despite these results, the effect of these 
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compounds on the reversal of damage that has already been caused by oxidative stress has 
not been investigated.  
The antioxidant efficacy of Mito-Q10 is due to its conversion to ubiquinol by 
complex II of the mitochondrial respiratory chain, but its reoxidation back to ubiquinone 
by complex III is ineffective. In ubiquinol form, Mito-Q10 quenches ONOO– and becomes 
oxidized, which can be reduced by complex II to ubiquinol, making it available to quench 
more ONOO– (James et al., 2005). Mito-Q10 may be effective in preventing the nitration 
of MnSOD and may serve as an effective therapeutic intervention to slow the progression 
of AD.  
Mitochondrial respiratory dysfunction and oxidative stress have been associated 
with many neurodegenerative diseases (Beal, 1995).  Results obtained in this study on 
mitochondrial respiration using pyruvate plus malate as substrate demonstrate that in 
APP/PS-1 mice there is inhibition of NAD-linked state 3 respiration rate, which is 
mediated through complex 1 of the mitochondrial electron transport chain.  RCR 
represents functional integrity of isolated mitochondria (Yen et al., 1999).  A high value 
of RCR indicates the utilization of substrates is tightly coupled to the production of ATP.  
The respiration injury would predict a low coupling efficiency of the mitochondrial 
electron transport and an increased likelihood of electron leakage during respiration, 
leading to O2–. radical formation and increased oxidative stress.  Our finding is consistent 
with that of Kokoszka and colleagues (Kokoszka et al., 2001) who reported a decrease in 
state III respiratory states and the RCR of liver mitochondria from both homozygous and 
heterozygous knock-out mice for the gene encoding the MnSOD protein, sod 2.  Cardiac 
mitochondria from sod 2 +/– mice, which have 50% reduction in MnSOD activity, showed 
altered mitochondrial function as exemplified by decreased respiration by complex I and 
an increase in the sensitivity of the permeability transition pore induction (Van Remmen 
et al., 2001).  Thus, mitochondria from the heart (sod 2 +/–) and liver (sod –/– and sod2 +/–) 
show evidence of increased oxidative damage compared with mitochondria isolated from 
sod2 +/+ mice.  Yen and colleagues (Yen et al., 1999) showed that MnSOD selectively 
protected state 3 respiration activity through complex I substrates and prevented    
complex I inactivation in heart mitochondria treated with the anthracyclin antibiotic, 
adriamycin.  These results indicate that MnSOD plays a critical role in oxidative stress 
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responses and in maintenance of mitochondrial respiration and the lack or reduced 
activity that leads to increased sensitivity of the animals to oxidative stress-induced 
mitochondrial damage.  The decreased activity of MnSOD in APP/PS-1 mice can be 
implicated as a cause of decreased state 3 respiration rate seen in these mice.  Our study, 
which shows a decline in mitochondrial respiration in aged (9 and 12 months) WT mice, 
also implicates the effects of mitochondrial ROS production in the process of aging.  Our 
findings are consistent with studies that demonstrate a decline in respiratory function of 
mitochondria with age (Wei and Lee, 2002; Yen et al., 1989) and decreased 
mitochondrial respiratory function in aged or aging mice, due to deficiencies in the 
MnSOD (Kokoszka et al., 2001).  Our results also suggest that nitrative inactivation of 
MnSOD may be, at least in part, responsible for the decline in the mitochondrial function 
of aging AD mice.  Biochemical analyses of brain specimens from patients with AD have 
shown abnormalities in the components of electron transport chain, particularly in the 
activity of cytochrome oxidase (COX) (Kish et al., 1999; Maurer et al., 2000).  Inhibition 
of COX could cause depressed ATP synthesis and bioenergetic impairment in AD.  In 
addition, the decreased COX function could cause diversion of electrons from their 
normal pathway into reaction with molecular oxygen in the neocortex and hippocampus 
in AD, resulting in increased O2–.(Markesbery, 1997).  Superoxide can contribute to 
mitochondrial impairment by generating additional reactive species, particularly hydroxyl 
radical, and peroxynitrite that can inactivate mitochondrial proteins leading to further 
decline in mitochondrial respiration, decreased ATP production, and ultimately neuronal 
cell death (Eckert et al., 2003).  
Although there is no consensus about the activity level of MnSOD in AD, there 
have been reports of reduction of SOD activity in AD frontal cortex, hippocampus, and 
cerebellum (Richardson, 1993) and elevation of SOD activity in the caudate nucleus of 
AD (Marklund et al., 1985).  However, there are reports of increased nitrotyrosine 
immunoreactivity in neurons of AD (Good et al., 1996; Vodovotz et al., 1996).  To our 
knowledge the identity of the nitrated proteins in the AD brain is not known.  Our results 
showing decreased activity of MnSOD in relation to age and nitration represents the first 
study directed to the identification of nitrated proteins in AD brain.  
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The mouse model used in our study has the sequence of Aβ identical to the human 
sequence. Further, the mutations introduced are driven by endogenous promoters of APP 
and PS-1 genes, and expression is limited to the replacement of these two endogenous 
genes and not by the expression of multiple transgenes.  The amyloid pathology observed 
in this model is similar to that found in AD. Thus, the results obtained from this model 
may prove useful in unraveling the pathogenesis of AD-induced oxidative stress.  
In conclusion, in this study we demonstrate an increased and accelerated 
deposition of Aβ in APP/PS-1 mice, increased levels of Aβ1-40/1-42, increased 
nitrotyrosine and subsequent inactivation of MnSOD, and impaired mitochondrial 
respiration in APP/PS-1 mice in association with age.  The increased levels of Aβ1-40/1-
42, essential for aggregation and subsequent neurotoxic properties, are observed from 6 
months on.  It is tempting to speculate that the increased Aβ may be the cause of 
alterations seen in MnSOD and the associated decrease in mitochondrial function.  These 
changes may lead to altered function of mitochondrial permeability transition pore (Yen 
et al., 1989), which increases the propensity to undergo apoptosis.  This is important 
because findings indicate that neuronal cell death associated with Aβ peptide are 
apoptotic in nature (Dickson, 2004).  Thus, our studies which indicate mitochondrial 
dysfunction, an age-associated increase in nitration of MnSOD, and its concomitant 
decrease in antioxidant activity, may provide the missing link between Aβ-induced 
oxidative stress and progression of AD.  
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CHAPTER THREE 
 
PEROXYNITRITE INDUCED NITRATION OF MnSOD REVEALS A NOVEL 
MECHANISM FOR THE REGULATION OF METABOLIC SWITCH IN 
NEURONAL CELLS 
 
ABSTRACT 
 
The energy demand of a cell is met predominantly by oxidative phosphorylation 
and glycolysis, both capable of mutual compensation.  Because the mitochondrial 
electron transport chain can generate superoxide radicals during the process of ATP 
production, which leads to mitochondrial dysfunction, we investigated whether 
inactivation of Manganese superoxide dismutase (MnSOD), a critical antioxidant enzyme 
in mitochondria, would lead to an increase in glycolysis for ATP production.  Here we 
report that exposure of SH-SY5Y cells to 250 μM peroxynitrite treatment leads to 
MnSOD nitration and subsequent reduction in activity.  MnSOD activity was inactivated 
at a concentration of peroxynitrite 10 times lower than that required to inhibit 
mitochondrial respiration.  Compromised mitochondrial function was demonstrated by 
the reduced activity of complex I and inhibition of MTT reduction.  The loss of    
complex I activity was alleviated by SOD mimetic and was reproduced by MnSOD 
siRNA.  The decline in mitochondrial function of peroxynitrite treated cells did not result 
in decreased ATP levels but was accompanied by an up-regulated glycolysis signified by 
high levels of lactate and lactate dehydrogenase activity but decreased activity of 
pyruvate dehydrogenase.  These changes were reversed by SOD mimetic and were 
promoted by MnSOD siRNA, linking the effect of reduced MnSOD activity to a switch 
in the cell’s energy production mechanism.  Specific reduction of MnSOD in MnSOD 
heterozygous knock-out mice led to decreased RCR and complex I activity with 
increased lactate levels, further supporting the role of MnSOD in regulating energy 
metabolism switch.  Our results suggest that glycolysis plays a role in sustaining cellular 
energy requirements under pathological conditions with MnSOD deficiency.  
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INTRODUCTION 
 
Aerobic organisms use O2 to facilitate the synthesis of energy in the form of ATP 
mainly by two routes, glycolysis in cytosol and oxidative phosphorylation in the inner 
mitochondrial membrane (Kadenbach, 2003).  Oxidative phosphorylation comprises a 
respiratory chain consisting of three proton pumps or complexes and produces the 
majority of ATP that cells require.  Aerobic organisms use O2 as a terminal electron 
acceptor for optimal energy release by mediating the transfer of single electrons (Nohl et 
al., 2004) through these complexes.  The electrons from reduced substrates are passed 
from complexes I and II of the electron transport chain through complexes III and IV to 
oxygen, forming water and causing protons to be pumped across the mitochondrial inner 
membrane (Brand et al., 2004).  But in circumstances of energy deficiency caused by 
compromised mitochondrial function, enhanced glycolytic capacity exists, even in the 
presence of high O2 concentration (Pedersen, 2007; Schoonen et al., 1990; Warburg, 
1956; Wu et al., 2007).  Mitochondrial dysfunction can occur due to accumulation of 
oxygen-derived reactive species such as hydroxyl radical and peroxyl radicals, and 
nonradical molecules such as singlet oxygen and hydrogen peroxide (Oberley, 2001),  
collectively called reactive oxygen species (ROS).  ROS are formed by the nature of 
oxygen, which is predisposed for univalent reductions (Fridovich, 1999).  Electrons can 
leak from the respiratory chain and react with oxygen to form superoxide radicals  (O2.-).  
Thus, superoxide radicals can be considered the parent radical from which other oxygen 
radicals and non-radicals are derived (Nohl et al., 2004).  Approximately 90% of  cellular 
ROS can be traced to oxidative phosphorylation in mitochondria (Balaban et al., 2005).  
Initial observations suggest that up to 5% of the total molecular oxygen utilized by 
mammalian mitochondria was converted into ROS (Boveris and Chance, 1973), but more 
recent analysis estimates that about 1-2% was converted into O2.- anion (Cadenas and 
Davies, 2000).  Superoxide and other oxygen-derived reactive species (Brand et al., 
2004) directly or indirectly can damage proteins, lipids and DNA.  To prevent  ROS-
induced injury, cells are equipped with an elaborate repertoire of antioxidant defense 
systems (Halliwell and Gutteridge, 2007).  There are three major primary intracellular 
antioxidant enzymes in mammalian cells that can remove ROS: superoxide dismutase 
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(SOD), catalase (CAT), and peroxidase, of which glutathione peroxidase (GPx) (Oberley, 
2001) and peroxiredoxin (Prx) (Halliwell and Gutteridge, 2007) are the most prominent. 
The SODs catalyze the dismutation of O2.- into hydrogen peroxide (H2O2) and molecular 
oxygen.  Hydrogen peroxide is further detoxified by CAT, GPx (Halliwell and 
Gutteridge, 1989) and Prx to water.  Thus, two reactive species--O2.- and H2O2--are 
converted to water (Oberley, 2001) and molecular oxygen.  Any disturbance in the pro-
oxidant and anti-oxidant balance in favor of the former is defined as oxidative stress 
(Sies, 1985).  
  Among the antioxidant systems, SOD is considered the first line of defense 
against oxidative stress (Halliwell, 1999; Ho et al., 1998).  Four distinct SODs are found 
in human cells: a homodimeric cytosolic copper zinc SOD (CuZnSOD) (McCord and 
Fridovich, 1969), an mitochondrial inter-membrane space CuZnSOD (Okado-Matsumoto 
and Fridovich, 2001), an extra-cellular homotetrameric glycosylated CuZnSOD 
(Marklund, 1982) and a mitochondrial matrix homotetrameric manganese SOD 
(MnSOD) (Weisiger and Fridovich, 1973).  MnSOD is a critical antioxidant enzyme in 
aerobic organisms because under physiological conditions superoxide is mainly 
generated on the matrix side of the inner mitochondrial membrane where MnSOD is 
located (Balzan et al., 1999).  MnSOD is a homotetramer with identical 24-kd subunits 
and one manganese ion per subunit (Matsuda et al., 1990).  The mature protein is strictly 
a mitochondrial enzyme compartmentalized in the mitochondrial matrix, although it is 
encoded by the nuclear sod2 gene.  Studies performed by us and others have shown that 
an imbalance between antioxidants and oxidants leads to various pathological conditions 
which can be effectively prevented or alleviated by increased MnSOD (Keller et al., 
1998; St Clair et al., 1991; Yen et al., 1996).  The over-all importance of this enzyme is 
evident from transgenic animal studies, wherein the MnSOD knock-out mice usually died 
within 10 days after birth with cardiac abnormalities, fat accumulation in liver and 
skeletal muscle (Lebovitz et al., 1996; Li et al., 1995) and metabolic acidosis (Lebovitz et 
al., 1996); and the animals that survived  longer than 10 days soon succumbed to severe 
anemia and neurodegeneration (Melov et al., 1998).  It has been demonstrated that 
MnSOD heterozygous knock-out mice show altered mitochondrial function, as illustrated 
by decreased respiration by complex I and  increased  sensitivity of  permeability 
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transition pore induction (Van Remmen et al., 2001), while overexpression of MnSOD 
protects complex I from inactivation (Yen et al., 1999).  Thus, it is likely that MnSOD 
function influences mitochondrial function and oxidative phosphorylation, necessary 
machinery for the production of ATP in cells.   
MnSOD activity can be compromised by a post-translation modification, such as  
nitration of tyrosine residues in its subunits (Ischiropoulos et al., 1992).  Of the nine 
tyrosine residues in each subunit of the homotetrameric MnSOD protein, tyrosine 
residues 34, 45 and 193 have been shown to be nitrated, with nitration of tyrosine residue 
34 causing inactivation of MnSOD (MacMillan-Crow et al., 1998).  Nitration of 
biological macromolecules can be mediated by nitric oxide, nitrogen dioxide, nitrous 
acid, hypochlorous acid, nitrated aliphatic reactive intermediates and peroxynitrite 
(Ischiropoulos, 1998).  Peroxynitrite has been demonstrated to nitrate tyrosine 34 of 
MnSOD which leads to its inactivation (MacMillan-Crow et al., 1998; Yamakura et al., 
1998).  Extensive data implicate peroxynitrite (ONOO-) as a consistent mediator of 3-NT 
formation (MacMillan-Crow et al., 1996; Smith et al., 1996; Yamakura et al., 1998; 
Yamamoto et al., 2002).  Peroxynitrite is a powerful oxidant and cytotoxic agent formed 
by the reaction between the free radicals nitric oxide (NO) and superoxide (O2.-) at rates 
approaching diffusion limit (Beckman, 1996; Huie and Padmaja, 1993).  The half life of 
peroxynitrite is < 1s, and the homolytic cleavage results in the production of hydroxyl 
radicals which have a much more deleterious effect than peroxynitrite itself (Beckman, 
1996).  Peroxynitrite causes oxidative damage to lipids, DNA, carbohydrates, proteins 
and amino acids, such as cysteine, methionine, phenylalanine and tyrosine (Beckman and 
Koppenol, 1996; Ischiropoulos and al-Mehdi, 1995).  Externally added ONOO- has been 
shown to diffuse passively across lipid bilayers  (Denicola et al., 1998) over distances of 
1 - 10 μm (Radi, 1998) with a permeability coefficient comparable to water (Marla et al., 
1997).  Although one of the major oxidative modifications of proteins resulting from 
peroxynitrite is carbonyl formation from side-chain and peptide-bond cleavage, perhaps 
the best known property of ONOO- is its ability to nitrate free tyrosine and tyrosine 
residues in proteins (Ischiropoulos et al., 1992; Souza et al., 1999).  It has been 
demonstrated that ONOO- nitrates and inactivates MnSOD in chronic rejection human 
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renal allograft, which has been proposed to be a general mechanism for  amplification of 
ONOO- induced damage (MacMillan-Crow et al., 1996).  In addition to nitration of 
MnSOD,  ONOO- has also been shown to mediate inactivation of electron transport chain 
components and ATPase, thereby inhibiting electron transport and ATP synthesis (Radi 
et al., 1994) and increasing the rate of glycolysis (Bolanos et al., 1995).  However, it is 
unclear whether nitration of MnSOD is directly relevant to the observed peroxynitrite-
induced alteration in energy production.   
Bringing together the findings that MnSOD is sensitive to ONOO-, the role of 
MnSOD in maintaining mitochondrial function and the contribution of mitochondrial 
function to ATP production, we propose that nitrative inactivation of MnSOD is an 
important event in peroxynitrite-induced alteration in metabolism.  Here, we demonstrate 
that exposure of human dopaminergic neuron SH-SY5Y cells to peroxynitrite (ONOO-) 
leads to nitration and reduced activity of MnSOD.  This is accompanied by decreased 
mitochondrial function and complex I activity, and increased lactate levels, with no 
decrease in ATP levels.  The loss of mitochondrial function and complex I activity and 
increase in lactate levels are alleviated by the presence of SOD mimetic.  These results 
suggest a novel role of MnSOD in mediating control of mitochondrial function and 
energy production. 
 
MATERIALS AND METHODS 
 
Materials 
 
Peroxynitrite was generously provided by Dr. Timothy R. Miller, University of 
Texas at El Paso. All chemicals and reagents were purchased from Sigma-Aldrich (St. 
Louis, MO) with the exception of the following:  Nitro blue tetrazolium (NBT) was 
purchased from Fisher Bioreagents (Fairlawn, NJ); protease inhibitor set III from 
Calbiochem (La Jolla, CA); rabbit poly-clonal anti-nitrotyrosine from Cayman chemical 
(Ann Arbor, MI); rabbit poly-clonal anti-MnSOD from Upstate Technology (Lake Placid, 
NY); protein A/G agarose from Santa Cruz Biotechnology (Santa Cruz, CA); minimum 
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essential medium (MEM) from GIBCO (Grand Island, NY); and standard fetal bovine 
serum from Hyclone (Logan, UT).  SOD mimetic (MnIIITE-2-PyP5+) was prepared as 
previously described (Batinic-Haberle, 1999). 
 
Cell Culture 
 
SH-SY5Y, a human neuroblastoma cell line, was grown in MEM, supplemented 
with 10% fetal bovine serum, 1% antibiotics (penicillin / streptomycin / neomycin), 1% 
nonessential amino acids and 1 mM sodium pyruvate.  Cells were cultured at 370C in a 
humidified incubator with 5% CO2.   
 
Animals 
 
Heterozygous C57BL6 MnSOD knock-out mice (sod 2 +/-) were originally 
obtained from Dr. Charles J. Epstein, University of California at San Francisco, and 
maintained as previously described (Van Remmen et al., 1999).  The wild-type C57BL6 
mice used for generation of sod 2 +/- mice were purchased from Harlan (Indianapolis, IN).  
Characterization of MnSOD knock-out mice has been previously reported (Van Remmen 
et al., 1999).  A 30 – 80% decrease in MnSOD activity in all tissues (liver, kidney, lung, 
brain, heart, muscle, stomach and spleen) of the heterozygous offspring has been 
documented and no alterations in CuZnSOD, glutathione peroxidase or catalase activities 
were found.  All mice used in the experiments were euthanized by intraperitoneal 
injection with 68 mg/kg of Nembutal followed by cervical dislocation. The experimental 
procedures were approved by the Institutional Animal Care and Use Committee of the 
University of Kentucky.  
 
Isolation of mitochondria 
 
Three brains (excluding cerebellum) from each group were removed immediately 
after animals were euthanized and were homogenized in 5 ml of ice-cold mitochondrial 
buffer, pH 7.2, containing 0.225 mol/L D-mannitol, 0.075 mol/L sucrose, 20 mmol/L 
57
HEPES, 1 mmol/L EGTA and 1% bovine serum albumin in a Dounce homogenizer with 
a Teflon pestle.  The homogenized brain samples were then diluted with isolation buffer 
to a final volume of 10 ml and centrifuged at 4500 rpm for 5 minutes.  The supernatant 
was transferred to a fresh tube on ice; the pellets were resuspended in isolation buffer, 
and homogenized and centrifuged at 4500 rpm for 5 minutes.  The supernatants were 
combined and centrifuged at 10,000 rpm for 20 minutes.  The brown mitochondrial 
pellets were resuspended in 200 μl of respiration buffer or phosphate buffered saline, as 
required.  Protein concentration was assessed by Bradford assay.  The isolated 
mitochondria were used for immunoprecipitation of nitrated MnSOD, assessment of 
oxygen consumption and activity of MnSOD.  
 
Immunoprecipitation of Nitrated MnSOD 
 
Isolated mitochondrial protein from the mouse brain or SH-SY5Y cell lysate (300 
μg) was resuspended in 200 μl of RIPA buffer (10 mM TRIS, 150 mM NaCl, 1% sodium 
deoxycholate, 1% Triton X-100 and 0.1% SDS, pH 7.5).  Rabbit polyclonal nitrotyrosine 
antibody (3 μg/ml) was added and incubated overnight at 40C.  Protein A/G agarose 
beads were added to the mixture and incubated overnight at 40C.  Immunocomplexes 
were collected by centrifugation at 12,000 rpm for 5 minutes at 40C, followed by washing 
the complexes with RIPA buffer three times.  The immunoprecipitated complexes were 
resuspended in 2X sample buffer, boiled for 5 minutes, fractionated by reducing 
SDS/polyacrylamide gel electrophoresis (PAGE) and analyzed by Western blot using 
rabbit polyclonal MnSOD antibody. 
 
Assessment of ATP 
 
SH-SY5Y cells were plated at a density of 3 x 105 cells/well and treated with 
indicated concentrations of peroxynitrite for 24 hours.  The cells were collected in 1X 
phosphate buffered saline (PBS) after washing twice with 1X PBS.  The cells were lysed 
by three freeze-thaw cycles.  The cell lysate was used to assess the ATP level, using the 
kit developed by Molecular probes (Invitrogen, Eugene, OR) according to the 
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manufacturer’s instructions, and analyzed by T20/20 luminometer.  The tests were 
repeated three times in triplicate. 
 
Measurement of Glucose 
 
Cell lysate prepared as described above for assessment of ATP was used to 
determine glucose concentration using the Amplex Red glucose/glucose oxidase assay kit 
developed by Molecular probes (Invitrogen, Eugene, OR) as per the manufacturer’s 
instructions.  The analysis was performed three times in triplicate.  
 
Determination of Lactate level 
 
Brains (excluding cerebellum) from MnSOD hetezygous knock-out (sod 2 +/-) 
mice were collected and washed twice in ice-cold PBS, and homogenized in Dounce 
homogenizer using Teflon pestle.  The homogenate was centrifuged at 5000 rpm for 5 
minutes and the supernatant was used to determine the concentration of lactate.  The SH-
SY5Y cell lysate, as described for assessment of ATP, was used to estimate the lactate 
level.  The reaction mixture contained 2M Tris; pH 7.5 in water with 0.05% sodium 
azide, stored at room temperature; 60 mM NAD+ in water, stored at -200C; 15 mM INT, 
prepared in water containing 10% (v/v) acetone; 100 units/ml Dase in 75 mM Tris; pH 
7.5 stored at -200C; and 50 units/ml of lactate dehydrogenase (LDH).  Just prior to the 
beginning of the assay, Dase was diluted 1:100 with 75 mM Tris, pH 7.5.  For the assay, 
50 μl of the reaction reagent was added to 20 μl of the cell lysate in a 96-well flat bottom 
microtitre plate.  The reaction was allowed to continue for 40 minutes in a humidified 
incubator without CO2.  The reaction was stopped by adding 50 μl of 3% acetic acid, 
followed by a brief agitation.  The absorbance was measured at 492 nm using a Spectra 
Max Gemini plate reader from Molecular Devices.  The reaction is based on the 
production of NADH and pyruvate from NAD and lactate by LDH.  This reaction is 
coupled to Dase-catalyzed reoxidation of NADH to NAD and reduction of INT to red 
colored formazan which is read at 492 nm.  The intensity of the red color is proportional 
to the concentration of lactate in the sample.   
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Activity of Lactate Dehydrogenase 
 
Lactate dehydrogenase (LDH) activity was assayed in the cell lysate of SH-SY5Y 
cells treated with 250 μM peroxynitrite for 24 hours.  The cells were washed twice with 
1X PBS, collected in 1X PBS and homogenized using a hand homogenizer for 30 
seconds.  This was repeated three times with 30 second intervals.  The homogenized cell 
lysate was used immediately to determine LDH activity, following the method described 
by Yen et al. (Yen et al., 1996).  Briefly, the cell lysate was added to a solution 
containing NADH and incubated at room temperature for 20 minutes.  Sodium pyruvate 
(22.7 mM) in 0.1 M potassium phosphate buffer (pH 7.5) was added after 20 minutes.  In 
the assay, the reaction where pyruvate is converted to lactate catalyzed by LDH is 
followed for two minutes.  The decrease in absorbance (dA/min – change in 
absorbance/minute) at 340 nm that occurs with the oxidation of NADH to NAD is used 
for calculating the LDH activity using the extinction coefficient of 6.22 mM-1cm-1 for 
NADH.  The activity was measured in three independent experiments, each in triplicate. 
 
Activity of Pyruvate Dehydrogenase 
 
The assay is based on the linking of the NADH produced by PDH to reduction of 
the dye INT and was performed as described by Elnageh & Gaitonde (Elnageh and 
Gaitonde, 1988).  Briefly, the final reaction mixture of 1 ml volume consisted of 50 mM 
Tris-HCL, 0.5 mM EDTA and 0.2% (wt/vol) Triton X-100 (pH 7.8), 20 μL of the cell 
lysate, 2.5 mM NAD, 0.1 mM CoA, 1 mM MgCl2, 0.1 mM oxalate, 1 mg of bovine 
serum albumin, 0.6 mM INT, 5-7 units of lipoamide dehydrogenase, 0.2 mM TPP and 5 
mM pyruvate.  After the addition of 4 mM TPP the contents were kept at 370C for 5 
minutes.  A stable baseline at 500 nm was obtained for the reaction mixture.  The reaction 
was started by adding 100 mM pyruvate.  The absorbance of the mixture at 500 nm was 
recorded at the beginning and again after the reaction had been underway for 5 minutes at 
370C.  Data was obtained from three independent experiments with triplicate samples. 
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MTT Assay 
 
The conversion of MTT dye to formazan dye crystals has been demonstrated to be 
related to  mitochondrial respiratory chain function (Musser and Oseroff, 1994).  Cells 
were plated at a concentration of 2 x 104 cells/well and treated with the indicated 
concentrations of peroxynitrite or SOD mimetic (1000 pg/ml).  MTT (1 mg/ml) was 
added to the cell cultures and incubated for 45 minutes.  Cells were then washed three 
times with PBS, solubilized in dimethylsulfoxide, and the absorbance was quantified at 
540 nm using a Spectra Max Gemini plate reader from Molecular Devices.  The data was 
obtained from three independent experiments with six replications each.  
 
Activity of Complex I 
 
Brains (excluding cerebellum) from sod 2 +/- mice were collected and washed 
twice in ice-cold PBS, and homogenized in Dounce homogenizer using Teflon pestle.  
The homogenate was used to estimate the activity of complex I.  SH-SY5Y cells treated 
with 250 μM of ONOO
-
 for 24 hours were washed twice in 1X PBS, collected in 
hypotonic buffer (20 mM potassium buffer, pH 7.2) and lysed by three cycles of fast 
freeze-thaw.  The specific activity of complex I was assayed as described previously 
(Lash and Jones, 1993), with slight modifications.  Briefly, the assay mixture containing 
25 mM of potassium phosphate buffer (pH 7.2), 5 mM MgCl2, 2 mM KCN, 2.5 mg/ml 
bovine serum albumin (fraction V), 0.13 mM NADH, 65 μM coenzyme Q5 and 2 μg/ml 
antimycin A were incubated at 300C for 1 minute.  The cell lysate/brain homogenate was 
added to initiate the reaction and the initial rate of NADH oxidation was monitored at 
340 nm (ε 6.81 mM-1 cm-1) for 1 minute.  The complex I specific activity was inhibited 
by 2 μg/ml of rotenone.  Complex I activity was calculated by the differences in dA/min 
with and without rotenone.  Activity was determined from three independent 
experiments, in triplicate, for cells and from three mice.  
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Activity of MnSOD 
 
SOD activity in the isolated mitochondria from brains of wild-type (WT) mice or 
from SH-SY5Y cell lysate was measured by the nitro blue tetrazolium (NBT)-
bathocuprione sulfonate reduction inhibition method (Spitz and Oberley, 1989).  This 
assay is based on the competitive reaction between SOD and the indicator molecule NBT 
for superoxide radicals generated by xanthine/xanthine oxidase.  The reduction of NBT is 
progressively inhibited in relation to addition of protein (containing SOD activity).  
Because potassium cyanide (5 mmol/L) was used to inhibit Cu/ZnSOD, this method 
measured only MnSOD activity.  The assay mixture also contained catalase to remove 
H2O2 and diethylenetriaminepentaacetic acid to chelate metal ions capable of redox 
cycling and interfering with the assay system.  The reduction of NBT to blue formazan by 
superoxide with/without cell lysate or isolated brain mitochondria was measured 
spectrophotometrically at 560 nm at 250C.  The rate of NBT reduction in the absence of 
cell lysate or isolated brain mitochondria was used as the reference rate (0.02 ± 0.005 
absorbance/min).  The data were plotted as percent of inhibition of NBT reduction versus 
protein concentration.  One unit of SOD activity was defined as the amount of SOD 
protein that caused a 50% reduction in the background rate of NBT reduction.  The 
activity of MnSOD was determined in triplicate from three independent experiments.    
 
Mitochondrial Respiration Assay 
 
Mitochondrial protein (400 μg) was resuspended in the respiration buffer 
containing 0.25 mol/L sucrose, 50 mmol/L HEPES, 2 mmol/L MgCl2, 1 mmol/L EGTA, 
10 mmol/L KH2PO4 and 0.5% bovine serum albumin, pH 7.4.  Oxygen consumption was 
measured using a Clark-type electrode oxygraph (Hansatech Inc., Norfolk, UK) with 10 
mmol/L pyruvate and 5 mmol/L malate as substrate in the absence of ADP (state II 
respiration), and after addition of 300 mmol/L ADP (state III respiration).  The ATPase 
inhibitor oligomycin (100 μg/ml) was then added to inhibit mitochondrial respiration 
(state IV respiration).  The ratio between the rate of oxygen consumption/min of state III 
and state IV was used to calculate the respiratory control ratio (RCR). 
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RNA Interference 
 
siRNA (Thermoscientific Dharmacon, On-TARGETplus SMARTpool) was used 
to selectively knock-down MnSOD.  SH-SY5Y cells were plated at 40% confluence at 
the time of transfection and transfected with control siRNA or MnSOD siRNA using 
oligofectamine for 12 hours in a serum-reduced Opti-MEM (Invitrogen).  The cells were 
washed with 1X PBS 48 hours after transfection and lysed by incubating for 30 minutes 
with lysis buffer (25 mM Tris-phosphate, pH 7.8, 2 mM dithiothretol, 2 mM 1, 2 – 
diaminocyclohexane N, N, N’, N’ – tetraacetic acid, 10% glycerol and 1% Triton X-100).  
Suppression of MnSOD was analyzed by Western blot.  Briefly, equal amounts of cell 
lysate proteins were resuspended in 2X sample loading buffer and SDS-PAGE was 
performed on 12.5% polyacrylamide gels.  Proteins were transferred electrophoretically 
(100V, 1 hour) to nitrocellulose membranes (Schleicher & Schuell, Dassell, Germany).  
Membranes were blocked using 5% nonfat dried milk in 50 mmol/L Tris, pH 7.9, 150 
mmol/L NaCl, and 0.05% (v/v) Tween-20.  For detection of MnSOD, nitrocellulose 
membranes were incubated overnight at 40C with polyclonal MnSOD antibody at a 
dilution of 1:10000.  This was followed by incubation with horseradish peroxidase-
conjugated anti-rabbit secondary antibody.  Probed membranes were washed three times, 
and immunoreactive proteins were detected using enhanced chemiluminescence 
(Amersham Corp., Piscataway, NJ).  Western blot analysis was conducted three times; 
the representative blot is shown in the manuscript.  
 
Statistical analysis 
 
Data were evaluated using either analysis of variance (ANOVA) with post-hoc 
Tukey’s multiple comparison test or Student’s t-test.  A difference of p < 0.05 was 
considered significant. 
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RESULTS 
 
Peroxynitrite induced nitration and inactivation of MnSOD in SH-SY5Y cells 
 
It has been shown that MnSOD is nitrated at tyrosine residue 34 and subsequently 
inactivated by peroxynitrite (Yamakura et al., 1998).   The experimental model used in 
this study demonstrates nitrated MnSOD and is the first step toward establishing a cell 
culture model for investigating the effect of MnSOD inactivation on cellular metabolism.  
SH-SY5Y were treated with 250 μM peroxynitrite and incubated for 24 hours.  The 
presence of nitrated MnSOD was identified by immunoprecipitation using a polyclonal 
nitrotyrosine antibody followed by Western analysis of MnSOD protein.  
Immunodetection with polyclonal MnSOD antibody demonstrated an appreciable amount 
of nitrated MnSOD in cells treated with peroxynitrite (Figure 3.1A).   
To verify that the presence of nitrotyrosine in MnSOD is associated with reduced 
MnSOD activity, we measured MnSOD activity in cells treated with 250 μM 
peroxynitrite.  MnSOD activity in peroxynitrite treated cells was significantly reduced 
compared to control (Figure 3.1B).  
 
Alteration in mitochondrial function in SH-SY5Y cells is associated with MnSOD 
activity 
 
To determine whether the decreased activity of MnSOD is associated with 
decreased mitochondrial function, we performed MTT assay (a measurement of 
mitochondrial dehydrogenase function) in SH-SY5Y cells 24 hours after treatment with 
250 μM peroxynitrite.  Quantification of absorbance of the solubilized formazan at 540 
nm revealed a significant reduction (p < 0.001) (Figure 3.2A) in the MTT level in cells 
treated with peroxynitrite.     
We have previously demonstrated that overexpression of MnSOD protects 
complex I from Adriamycin induced inactivation (Yen et al., 1999).  To determine 
whether the observed decrease in MnSOD activity in peroxynitrite treated cells has any 
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Figure 3.1 Treatment with peroxynitrite induces nitration and reduced activity of
MnSOD in SH-SY5Y cells.
A. Immunoprecipitation (IP) of MnSOD tyrosine nitration. SH-SY5Y cell lysate was
precipitated with nitrotyrosine antibody and analyzed by Western blot using MnSOD
antibody. Positive control – Isolated brain mitochondria treated with 250 μM
peroxynitrite, Negative control – Isolated brain mitochondria precipitated with non-
immune rabbit IgG and analyzed by Western blotting using MnSOD antibody. PEL –
pellet, SUP – supernatant.
B. MnSOD activity in SH-SY5Y cells treated with 250 μM peroxynitrite was measured by
NBT-bathocuprione sulfonate reduction inhibition method. The activity was measured
in triplicate at 24 hours post treatment in three sets of independent experiments. *, p <
0.05, compared with the control.
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effect on the activity of complex I, we assessed the activity of complex I in SH-SY5Y 
cells treated with 250 μM peroxynitrite and incubated for 24 hours.  As shown in Figure 
3.2B, the activity of complex I was significantly reduced (p < 0.05) in comparison with 
the untreated control. 
 
SOD mimetic (MnIIITE-2-PyP5+) protects against peroxynitrite–induced 
mitochondrial dysfunction 
 
Although the reduced MnSOD activity and concurrent reduction in mitochondrial 
function and complex I activity are interrelated, the interrelationship does not 
demonstrate that reduction of MnSOD activity is a cause for reduced mitochondrial 
function. To further establish the role of MnSOD on mitochondrial function, we pre-
treated the SH-SY5Y cells for 24 hours with SOD mimetic and measured mitochondrial 
function after treatment with peroxynitrite.  Cells were pre-treated with SOD mimetic 
(1000 pg/ml) for 24 hours and then exposed to 250 μM peroxynitrite.  The results show 
that the loss of complex I activity was reduced in the cells with SOD mimetic pre-
treatment (p < 0.05) (Figure 3.3A).   
To verify further that MnSOD indeed contributes to mitochondrial function, we 
used the siRNA approach.  SH-SY5Y cells were transfected with control siRNA or 
MnSOD siRNA using oligofectamine.  Cells were harvested 48 hours after transfection 
and expression of MnSOD was verified by Western blot.  There was a substantial 
suppression of MnSOD level (Figure 3.3B) in the cells transfected with MnSOD siRNA.  
These transfected cells were used for determination of complex I activity.  The cells 
transfected with MnSOD siRNA showed significant decrease (p < 0.05) in complex I 
activity in comparison with untransfected control (Figure 3.3C).   
 
MnSOD activity is sensitive to peroxynitrite induced inactivation 
 
The results demonstrated in Figure 3.2 suggest that reduced activity of MnSOD 
may contribute to the loss of mitochondrial function.  They do not indicate, however, 
whether MnSOD activity or mitochondrial function is more sensitive to peroxynitrite-
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Figure  3.2   Peroxynitrite reduces mitochondrial complex I activity and mitochondrial 
function in SH-SY5Y cells.
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Figure 3.2 Peroxynitrite reduces mitochondrial complex I activity and mitochondrial
function in SH-SY5Y cells.
A. Mitochondrial function was assessed by the ability of the mitochondria to uptake and
reduce MTT, 24 hours after SH-SY5Y cells were treated with 250 μM peroxynitrite.
B. Complex I activity in SH-SY5Y cells treated with 250 μM peroxynitrite in the same
manner described in A. All measurements were performed in triplicate. The data are
averages from three sets of independent experiments. **, p < 0.01, *, p < 0.05,
compared with the control.
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Figure 3.3 SOD mimetic and MnSOD siRNA alter mitochondrial complex I
activity.
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Figure 3.3 SOD mimetic and MnSOD siRNA alter mitochondrial complex I activity.
A. SH-SY5Y cells were treated with SOD mimetic (1000 pg/ml) for 24 hours, followed by
treatment with 250 μM peroxynitrite for an additional 24 hours.
B. Western blot using polyclonal MnSOD and GAPDH antibody, csiRNA – control
siRNA, siRNA – MnSOD siRNA.
C. Complex I activity (nmoles/min/mg protein) in SH-SY5Y cells transfected with
MnSOD siRNA. The measurements were performed in triplicate. All data represent
the average of three independent experimental sets. *, p < 0.05, #, p < 0.05, compared
with the control and 250 μM ONOO respectively.
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induced inactivation.  To answer this question, we conducted a dose-response experiment 
in mitochondria isolated from mouse brain.  The isolated mitochondria were treated with 
0, 1, 10, 100 or 250 μM peroxynitrite for 1 minute and then oxygen consumption was 
measured as an indicator of mitochondrial respiration chain activity using a Clark-type 
electrode oxygraph with pyruvate and malate as substrates in the absence of ADP (state II 
respiration), or presence of ADP (state III respiration).  The ATPase inhibitor oligomycin 
was then added to inhibit mitochondrial respiration (state IV respiration).  The RCR was 
not affected and was comparable to the untreated control when exposed to 1 μM 
peroxynitrite, whereas the RCR was significantly decreased (p < 0.001) at all other 
concentrations of peroxynitrite (Figure 3.4A).  The data obtained from respiration 
analysis show that 1 μM did not affect the RCR, whereas the activity of MnSOD was 
significantly reduced (p < 0.01) at this concentration (Figure 3.4B).  This result indicates 
that MnSOD is inactivated by peroxynitrite at concentrations lower than what is required 
to observe the loss of mitochondrial respiration function.  
Concomitant with the reduced activity of MnSOD, immunoprecipitation 
performed on the mitochondria treated with 1 μM and 10 μM peroxynitrite demonstrated 
appreciable levels of nitrated MnSOD (Figure 3.4C).  This indicates that the observed 
reduced activity of MnSOD treated with 1 μM is associated with peroxynitrite-induced 
nitration of MnSOD. 
 
Peroxynitrite has no effect on cellular ATP levels 
 
Because treatment with peroxynitrite resulted in a reduction in mitochondrial 
respiration capacity, we explored the impact of this change on cellular ATP levels.  Cells 
were treated with 250 μM peroxynitrite and the total cellular levels of ATP were 
compared 24 hours after treatment   (Figure 3.5).  The level of ATP in peroxynitrite 
treated cells was comparable to that of control cells.  The cells treated with 2 
deoxyglucose (2DG), a glycolytic inhibitor used as a positive control, showed significant 
decrease (p < 0.001) in ATP levels in comparison with both untreated cells and 
peroxynitrite treated cells (Figure 3.5).   
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Figure 3.4 MnSOD activity is more sensitive to peroxynitrite than
mitochondrial respiration.
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Figure 3.4 MnSOD activity is more sensitive to peroxynitrite than mitochondrial
respiration.
A. RCR of isolated mitochondria protein from mouse brain tissues. RCR was calculated
as the ratio between state 3 and state 4 respirations. Mitochondria were exposed to the
indicated concentrations of peroxynitrite for 1 minute prior to the oxygen consumption
measurement.
B. MnSOD activity was measured from isolated mitochondrial protein treated with
indicated concentrations of peroxynitrite for 1 minute.
C. Nitrotyrosine containing mitochondrial protein was precipitated with nitrotyrosine
antibody and analyzed by Western blot using MnSOD antibody. Positive control –
Isolated brain mitochondria treated with 250 μM peroxynitrite, Negative control -
Isolated brain mitochondria precipitated with non-immune rabbit IgG and analyzed by
Western blotting using MnSOD antibody. PEL – pellet, SUP – supernatant. All
measurements were performed in triplicate. The data shown is the average of three
experimental sets. ***, p < 0.001, **, p < 0.01, compared with the control.
74
Figure 3.5 Peroxynitrite treatment does not alter ATP levels in SH-SY5Y cells. ATP
was measured in SH-SY5Y cells treated with 250 μM peroxynitrite or 5.5 mM 2DG for 24
hours. 2DG was used as positive control. The measurements were performed in triplicate.
The data represent an average from three sets of independent experiments. ***, p < 0.001,
compared with the control.
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Peroxynitrite mediated increase in glycolytic activity 
 
Because the total cellular ATP was maintained in cells with reduced respiratory 
function, it is possible that glycolysis may compensate for the production of ATP.  To 
address this question, we measured the concentration of lactate 24 hours after treating the 
SH-SY5Y cells with 250 μM peroxynitrite.  The concentration of lactate in cell lysate 
treated with peroxynitrite was significantly increased (p < 0.01) in comparison with the 
untreated controls (Figure 3.6A).   The activity of lactate dehydrogenase, an enzyme that 
catalyzes the conversion of pyruvate to lactate, was also significantly increased (p < 
0.001) in the cell lysates treated with 250 μM peroxynitrite (Figure 3.6B).  These results 
indicate that glycolytic activity increases in peroxynitrite treated cells. 
The increase in glycolytic activity suggests that peroxynitrite treated cells may 
have a higher level of glucose, which was assessed by the glucose concentrations in the 
cell lysate.  The results indicate that the concentration of glucose was significantly higher 
(p < 0.05) in peroxynitrite treated cells in comparison with control cells (Figure 3.7A).  
Pyruvate dehydrogenase (PDH) catalyzes the conversion of pyruvate to Acetyl-
CoA, which then enters the tri-carboxylic cycle.  Decreased activity of PDH would lead 
to accumulation of pyruvate, which can be converted to lactate by lactate dehydrogenase.  
To probe this possibility, we analyzed the activity of PDH in SH-SY5Y cells 24 hours 
after treatment with 250 μM peroxynitrite.  The results show that the activity of PDH was 
significantly decreased (p < 0.001) in peroxynitrite treated cells in comparison with the 
untreated control (Figure 3.7B). 
 
Suppression of MnSOD enhances glycolytic activity 
 
 The increase in glycolytic activity obtained in cells treated with peroxynitrite 
suggests that MnSOD has a role in this process.  To test this possibility, we reduced the 
MnSOD level by transfecting SH-SY5Y cells with control siRNA or MnSOD siRNA.  
The cells were harvested 48 hours after transfection and suppression of MnSOD was 
confirmed by Western analysis (data not shown).  The corresponding cell lysates were 
used for measurement of lactate concentration and LDH activity.  Both the lactate 
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Figure 3.6 Peroxynitrite increases the levels of lactate and activity of lactate
dehydrogenase in SH-SY5Y cells.
A. Concentrations of lactate.
B. Activity of LDH.
All these measurements were performed in triplicate. The data are the average of three
experimental sets. **, p < 0.01, compared with the control.
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Figure 3.7  Peroxynitrite increases the levels of glucose and suppresses the activity of 
pyruvate dehydrogenase in SH-SY5Y cells.   
A. Concentrations of glucose.
B. Activities of PDH.
All these measurements were performed in triplicate.  The data are the average of three 
experimental sets.  *, p < 0.05, **, p < 0.01, compared with the control.
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concentration (p < 0.01) and LDH activity (p < 0.05) were significantly increased in cells 
transfected with MnSOD siRNA (Figure 3.8A and B).  This increase in lactate levels 
suggests that increased glycolytic activity compensates for reduced respiration due to 
reduction of MnSOD activity.  
To test this possibility we investigated whether the compensatory increase in 
glycolytic activity is altered by the presence of SOD mimetic.  SH-SY5Y cells were pre-
treated for 24 hours with SOD mimetic (1000 pg/ml) followed by treatment with 250 μM 
peroxynitrite.  Lactate levels were significantly higher (p < 0.05) in the group treated with 
peroxynitrite alone.  However, in the SOD mimetic pre-treated group,  lactate levels were 
comparable to those of the control cells and were significantly less (p < 0.05) in 
comparison with the peroxynitrite treated group (Figure 3.9A).  This indicates that SOD 
mimetic protects the mitochondrial function and, thus, there is no compensatory increase 
in glycolytic activity.  The cells treated with mimetic showed significantly increased 
activity of pyruvate dehydrogenase (p < 0.01) in comparison with the group treated with 
peroxynitrite (Figure 3.9B). 
 
Decreased mitochondrial respiration and increased glycolytic activity in sod 2 +/- 
mice 
 
All the above observations made in-vitro suggest that reduction in MnSOD 
activity is associated with mitochondrial dysfunction and increase in glycolytic activity.  
To verify that this phenomenon is occurring in-vivo, we used sod 2 +/- mice.   MnSOD 
activity in sod 2 +/- mice has been shown to be decreased (30 – 80%) in all tissues 
examined in comparison with sod 2 +/+ mice (Van Remmen et al., 1999).  Three mice 
from both sod 2 +/- and WT mice were euthanized.  Brains (excluding cerebellum) were 
collected and used for analysis of mitochondrial respiration, complex I activity and 
lactate concentration.  The results show that the RCR of sod 2 +/- mice mitochondria was 
significantly reduced (p < 0.05) in comparison with WT mice (Figure 3.10A).   
The activity of complex I in whole brain homogenate was significantly reduced (p 
< 0.01) in comparison with WT mice (Figure 3.10B).  The respiration and activity of 
complex I indicate that the mitochondrial function in the brain of sod 2 +/- mice was 
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compromised.  To investigate whether glycolytic activity is increased to compensate for 
this loss of mitochondrial function, the concentration of lactate was evaluated.  The 
concentration of lactate was significantly higher in sod 2 +/- mice (p < 0.01) in 
comparison with WT mice (Figure 3.10C). 
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Figure 3.8 Suppression of MnSOD enhances the levels of lactate and activity of
lactate dehydrogenase.
A. Concentration of lactate.
B. Activity of Lactate dehydrogenase. All measurements were performed in triplicate.
csiRNA – control siRNA, siRNA – MnSOD siRNA.
The data are the average of three experimental sets. *, p < 0.05, **, p < 0.01, compared
with the control and csi RNA respectively.
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Figure 3.9 SOD mimetic (MnIIITE-2-PyP5+) (1000 pg/ml) suppresses the level of lactate
and increases the activity of pyruvate dehydrogenase.
A. Concentration of lactate.
B. Activity of PDH. All estimates were done in triplicate.
The data are the average of three experimental sets. *, p < 0.05, **, p < 0.01, compared with
the control; #, $, p < 0.05, compared with the 250 μM ONOO.
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Figure 3.10 MnSOD deficiency leads to alteration in oxygen consumption,
complex 1 activity and levels of lactate.
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Figure 3.10 MnSOD deficiency leads to alteration in oxygen consumption, complex 1
activity and levels of lactate.
A. Mitochondrial respiration in isolated mitochondria protein from brains.
B. Complex I activity and lactate levels in whole brain homogenate of sod 2 +/- mice.
C. Levels of lactate in whole brain homogenate of sod 2 +/- mice.
All measurements were performed in triplicate from three animals. *, p < 0.05, **, p < 0.01,
compared with the WT.
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DISCUSSION 
 
Manganese superoxide dismutase (MnSOD) is the only isoform of SOD found 
inside the mitochondrial matrix of eukaryotic cells (Quijano et al., 2001) and its presence 
is essential for the survival of aerobic life (Lebovitz et al., 1996; Li et al., 1995; Melov et 
al., 1998).  Mitochondria are major organelles where most of the cell superoxide is 
produced.  Thus, MnSOD plays a critical role in protecting the cell from superoxide 
radicals (Fridovich, 1975).     
 Mitochondria are essential for the production of ATP through oxidative 
phosphorylation, and it has been shown that peroxynitrite, a strong oxidant that is a 
product of nitric oxide and superoxide, can nitrate tyrosine 34 of MnSOD, thereby 
inactivating it (MacMillan-Crow et al., 1998).  We therefore asked whether inactivation 
of MnSOD by nitration influences the mode of energy production in mammalian cells.  
We treated SH-SY5Y neuroblastoma cells with peroxynitrite to induce nitration and 
subsequent inactivation of MnSOD.  The results demonstrate that there is a link between 
the shift in energy metabolism and nitrative inactivation of MnSOD in SH-SY5Y cells.  
The data indicate that reduction of MnSOD activity leads to a reduction in mitochondrial 
respiration and an increase in glycolytic activity.   
Nitration of biological macromolecules can be caused by nitric oxide, nitrogen 
dioxide, nitrous acid, hypochlorous acid, nitrated aliphatic reactive intermediates and 
peroxynitrite (Ischiropoulos, 1998).  But only peroxynitrite mediates the inactivation of 
MnSOD by exclusive nitration of tyrosine residue 34.  Tyrosine 34 is located at the 
vertex of the substrate channel and only 5 Å from the active manganese ion site of  
MnSOD (Yamakura et al., 1998).  This makes this residue most susceptible to nitration 
because   peroxynitrite is attracted to the active site by the basic residues in the channel 
entrance (Quijano et al., 2001) and  the ionization state of tyrosine 34 is altered by 
positively charged manganese atoms making it prone to an electrophilic attack 
(MacMillan-Crow et al., 1998).  Being a major player in removing superoxide, it is 
possible that nitration and inactivation of MnSOD would result in an increase in 
mitochondrial superoxide levels leading to enhanced generation of peroxynitrite, thereby 
85
amplifying the nitration/oxidation of mitochondrial proteins and eventually 
compromising mitochondrial function.   
The involvement of MnSOD activity in the maintenance of mitochondrial 
function has been amply documented by studies using sod 2 +/- mice that show a decrease 
in mitochondrial function as measured by reduced RCR for the substrates of complex I 
(Van Remmen et al., 2001).  The data obtained from our study of cells treated with 
peroxynitrite show that decreased activity of complex I is associated with nitration and 
inactivation of MnSOD.  Complex I function can be affected by either direct reaction of 
superoxide radicals that might accumulate because of reduced MnSOD activity or by 
direct inactivation of complex I by enhanced production of peroxynitrite (Cassina and 
Radi, 1996; Rusak et al., 2006).  Several lines of experiments indicate that MnSOD 
activity is important for the protection of mitochondrial function and complex I activity.  
First, the uptake and reduction of MTT, an indicator for mitochondrial function and 
complex I activity (Musser and Oseroff, 1994), are  reduced.  Second, it has been shown 
that overexpression of MnSOD selectively protects complex I inactivation in transgenic 
mice treated with adriamycin (Yen et al., 1999) and in lung carcinoma cells exposed to 
hypoxia-reoxygenation (Powell and Jackson, 2003).  Importantly, our data demonstrate 
that the loss in complex I activity in cells treated with peroxynitrite was alleviated by the 
presence of a SOD mimetic (MnIIITE-2-PyP5+) capable of localizing in the mitochondria.   
It should be noted that this result is confounded by the  ability of SOD mimetic (MnIIITE-
2-PyP5+) to be a scavenger of peroxynitrite (Ferrer-Sueta et al., 2003; Spasojevic et al., 
2007) but reduced activity of complex I exhibited in SH-SY5Y cells transfected with 
MnSOD siRNA is consistent with the role of MnSOD in protecting complex I activity.  
Since complex I represents a point of entry of electrons from NADH-linked 
substrates, loss of its activity probably will result in reduced electron flux to the 
respiratory chain (Radi et al., 1994) and thereby  mitochondrial function, and it therefore 
follows that reduced activity of MnSOD (Van Remmen et al., 2001) and exposure to 
peroxynitrite (Cassina and Radi, 1996) will result in compromised mitochondrial 
function.  Although there are multiple targets for peroxynitrite in mitochondria (Cassina 
and Radi, 1996; MacMillan-Crow et al., 1998; Rusak et al., 2006; Yamakura et al., 1998), 
our result demonstrates that MnSOD is an early target in the process of peroxynitrite-
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induced mitochondrial dysfunction.  MnSOD was inactivated at 1 µM peroxynitrite, but 
respiration was inhibited at 10- fold higher concentrations.  Given the transient nature of 
peroxynitrite in biological systems, the early inactivation of MnSOD, an important anti-
oxidant enzyme in the mitochondria, is of immense importance.  MnSOD can inhibit 
peroxynitrite formation in the mitochondria (Radi et al., 1994), but its inactivation can 
possibly lead to an increase in intramitochondrial superoxide levels and additional 
generation of peroxynitrite (MacMillan-Crow et al., 1996).  This can propagate the initial 
damaging event that leads to mitochondrial dysfunction (Radi et al., 1994).  Further proof 
of the involvement of MnSOD in protecting mitochondrial function is the decreased 
activity of complex I and reduced RCR in sod 2 +/- mice.  Our results are consistent with 
the results from an earlier study showing a reduction of RCR and state III respiration in 
mitochondria isolated from the heart of Sod 2 +/- mice (Van Remmen et al., 2001) and 
extend to demonstrate the effect of MnSOD in brain mitochondria.  Together these data 
demonstrate an important role for MnSOD in protecting the respiratory function of 
mitochondria.   
Mitochondrial respiration is the most important contributor to the cell’s energy 
requirement, producing 32 ATPs from one glucose molecule.  Thus, dysfunction of 
respiratory complexes would eventually lead to compromised respiration and thereby loss 
of ATP generation from oxidative phosphorylation.  The ability of cells to shift from 
oxidative phosphorylation to glycolysis has been observed in many tumors with impaired 
mitochondrial function (Gatenby and Gillies, 2004).  Our data suggest that both           
SH-SY5Y cells treated with peroxynitrite and brain tissue in MnSOD deficient mice were 
capable of maintaining their required energy by up- regulating glycolytic activity.  The 
lactate levels in cells treated with peroxynitrite were increased in comparison with control 
cells, suggesting increased glycolytic activity.  These results are consistent with those 
obtained from platelets (Rusak et al., 2006) and primary neuronal cells (Bolanos et al., 
1995) exhibiting decreased mitochondrial respiration when treated with peroxynitrite.  
The conversion of pyruvate to lactate is catalyzed by the NADH-dependent enzyme, 
lactate dehydrogenase (LDH).  Compared with the untreated cells, peroxynitrite treated 
cells exhibited a higher activity of lactate dehydrogenase which was similar to the 
observed increased lactate levels.  The activities of mitochondria and LDH are delicately 
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and mutually regulated at the level of metabolites.  They depend on the availability of 
pyruvate and NADH/NAD+.  Pyruvate accumulates in the cell under conditions of 
decreased activity of pyruvate dehydrogenase, which oxidizes pyruvate to acetyl-coA, 
thereby facilitating the entry of pyruvate into kreb’s cycle.  Consistent with this model, 
we found reduced activity of PDH in cells treated with peroxynitrite.  The fast kinetics of 
LDH ensures that accumulated pyruvate is converted to lactate (Fantin et al., 2006).  
Pyruvate to lactate conversion utilizes NADH and regenerates NAD+ which can be used 
to drive glycolysis, which produces more lactate.  As more and more NADH is consumed 
for this reaction, less NADH is available for mitochondrial respiration, thereby slowing 
down the already impaired respiration in cells treated with peroxynitrite.  A high rate of 
conversion of glucose to lactate is coupled to a high rate of glucose uptake and glucose 
phosphorylation and occurs even in the presence of normal oxygen pressure (Gatenby 
and Gillies, 2004).  In this study, SH-SY5Y cells treated with peroxynitrite also showed 
significantly increased levels of glucose.  Thus, it seems probable that impaired 
mitochondrial function due to reduced MnSOD activity leads to a compensatory increase 
in glycolysis.  This possibility is further supported by the finding that cells transfected 
with MnSOD siRNA have increased levels of lactate and lactate dehydrogenase activity.  
Compensating for SOD activity with a SOD mimetic in the cells treated with 
peroxynitrite resulted in reduction of lactate concentration and alleviation of PDH 
activity.  Our results from in-vivo experiments with sod 2+/- mice demonstrate increased 
lactate levels in the brain.  Those results further support the likelihood that alteration in 
MnSOD activity plays a key role in reducing mitochondrial function and subsequently 
compensating for the energy requirements of cells by the up- regulation of glycolytic 
activity.   
Increased nitrotyrosine has been documented in hippocampus and cerebral cortex 
of aged rats (Shin et al., 2002), cerebrospinal fluid of aged humans (Tohgi et al., 1999) 
and in many neurodegenerative disorders (Torreilles et al., 1999).  The identities of many 
proteins modified by nitration have been obtained in human, animal and cellular models 
of diseases (Ara et al., 1998; Sultana et al., 2006).  However, MnSOD was the first 
protein  unequivocally identified as nitrated in chronic rejection of human renal allografts 
(MacMillan-Crow et al., 1996).  A previous study from our lab has shown the presence of 
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nitrated MnSOD in brains of APP/PS-1 double knock-in mouse model of Alzheimer’s 
disease (Anantharaman et al., 2006).  To our knowledge, this is the first study to 
implicate the inactivation of MnSOD to the metabolic switch occurring under conditions 
of mitochondrial dysfunction.   
In summary, we demonstrate that MnSOD was nitrated upon peroxynitrite 
treatment with an associated decrease in activity.  Inactivation of MnSOD is an early 
event in peroxynitrite-induced impairment of mitochondrial function.  Mitochondrial 
dysfunction was compensated for by an increase in glycolytic activity.  Mitochondrial 
dysfunction and increased glycolytic activity were prevented by SOD mimetic and 
enhanced by MnSOD deficiency.  These results demonstrate a critical role for MnSOD in 
maintaining mitochondrial respiratory function and reveal the role of glycolysis in 
sustaining cellular energy requirements under pathological conditions associated with 
MnSOD deficiency. 
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CHAPTER FOUR 
 
INCREASED GLYCOLYSIS IN THE APPNLh/NLh X PS-1P264L/P264L DOUBLE 
KNOCK-IN MOUSE MODEL OF ALZHEIMER’S DISEASE 
 
ABSTRACT 
 
Altered energy metabolism is characteristic of many neurodegenerative disorders.  
In AD patients, memory dysfunction is associated with glucose hypometabolism and 
neuronal loss in the hippocampus.  In addition to the role in the pathogenesis of AD, Aβ 
peptide has been associated with reduced glucose oxidative metabolism and 
mitochondrial activity.  Here, brains from APPNLh/NLh X PS-1P264L/P264L Double Knock-In 
Mouse Model of Alzheimer’s disease (APP/PS-1) were used to investigate a possible 
change in glycolytic activity.  We estimated the levels of lactate, the activity of lactate 
dehydrogenase (LDH) and pyruvate dehydrogenase (PDH) from 3 and 14-16 months old 
APP/PS-1 mice and wild-type (WT) mice.  Significantly increased lactate levels were 
observed in 14-16 months old APP/PS-1 mice when compared to their age-matched WT 
counterparts.  The activity of LDH was also significantly increased in the APP/PS-1 
mice.  PDH appears to have age associated decrease in activity and was significantly 
decreased in APP/PS-1 mice when compared to age-matched WT mice.  These findings 
implicate a possibility of an increased glycolytic activity in APP/PS-1 mice.   
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INTRODUCTION 
 
Glucose is an essential energy source for the adult human brain.  The brain is 
metabolically the most active organ and is therefore highly dependent on a continuous 
supply of its fuel.  To meet its very high energy demands, the brain (around 1/40 of the 
body weight) prossesses a relatively high blood flow and glucose consumption equal in 
amount to about one-fifth of the entire resting requirements of the body (Roeder et al., 
1982).  When the blood glucose levels fall by half from a normal fasting value (to about 2 
– 3 mM), there is some cognitive impairment and, at glucose levels below 1 mM, mental 
confusion is evident and coma may result from sustained glucose deprivation.  
Modern humans acquired enhanced longevity accompanied by the expansion of 
lifetime in nonreproductive ages.  However, this prolonged lifetime brought up negative 
assets: late-onset diseases such as AD.  Reported characteristics of AD brain are impaired 
energy metabolism, and increased oxidative stress (Fukui et al., 2007).  Early impairment 
of memory and learning are characteristic features of AD.  These symptoms correspond 
well to the glucose hypometabolism present even at early stages of the disease when only 
mild cognitive impairment is evident clinically (de Leon et al., 2001; De Santi et al., 
2001).   Most of the evidence suggesting an impairment of cerebral energy metabolism 
has come from in vivo studies as detected by reduced cortical [18F] deoxyglucose uptake 
using positron emission tomography (Mielke et al., 1996).  Accordingly, activities of key 
glycolytic enzymes like hexokinase, aldolase, pyruvate kinase, lactate dehydrogenase and 
glucose – 6 – phosphate dehydrogenase were found to be altered in AD patients (Bigl et 
al., 1999) along with a reduction in densities of glucose transporter subtypes (GLUT1 and 
GLUT 3) (Bigl et al., 2003).  However, with respect to several other enzymes the results 
have been contradictory.   
Transgenic animals developed to model AD pathology by overexpression of 
mutated form of APP and PS-1 also demonstrate decreased hippocampal glucose 
metabolism with a positive correlation to the deposition of Aβ plaque (Sadowski et al., 
2004).  Here a APPNLh/NLh X PS-1P264L/P264L Double Knock-In Mouse Model of 
Alzheimer’s Disease (APP/PS-1) carrying a Swedish familial AD mutation in amyloid 
precursor protein and having the P264L familial AD mutation in presenilin – 1 (Chapter 
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two) were used to investigate a possible change in glycolytic activity.  This mouse has 
been demonstrated to display increased Aβ deposition from 6 months onwards consistent 
with an increase in the levels Aβ 1-40 and Aβ 1-42.  The finding of increased glycolytic 
activity in the event of decreased mitochondrial function in SH-SY5Y cells (Chapter 
three) in association with decreased activity of MnSOD prompted us to investigate 
whether APP/PS-1 mice with decreased mitochondrial function (Chapter two) 
(Anantharaman et al., 2006) has an increase in glycolytic activity.  A significant increase 
in lactate levels was observed in 14-16 months old APP/PS-1 mice when compared to 
age-matched WT mice.  The activity of LDH was also significantly increased in the same 
age group.  PDH appears to have an age associated decrease in activity that was 
significantly decreased in all age groups when compared to age-matched WT mice.  
These findings implicate a possibility of an increased glycolytic activity in APP/PS-1 
mice.   
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MATERIALS AND METHODS 
 
Determination of Lactate levels 
 
Brains (excluding cerebellum) from six animals from both APP/PS-1 and WT 
mice of 3- and 14-16 month old were collected and washed twice in ice-cold PBS, and 
homogenized in Dounce homogenizer using Teflon pestle.  The homogenate was 
centrifuged at 5000 rpm for 5 minutes and the supernatant was used to determine the 
concentration of lactate.  The reaction mixture contained 2M Tris; pH 7.5 in water with 
0.05% sodium azide, stored at room temperature; 60 mM NAD+ in water, stored at -200C; 
15 mM INT, prepared in water containing 10% (v/v) acetone; 100 units/ml Dase in 75 
mM Tris; pH 7.5, stored at -200C; and 50 units/ml of lactate dehydrogenase (LDH).  Just 
prior to the beginning of the assay, Dase was diluted 1:100 with 75 mM Tris, pH 7.5.  For 
the assay, 50 μl of the reaction reagent was added to 20 μl of the cell lysate in a 96-well 
flat bottom microtitre plate.  The reaction was allowed to continue for 40 minutes in a 
humidified incubator without CO2 at 370C.  The reaction was stopped by adding 50 μl of 
3% acetic acid, followed by a brief agitation.  The absorbance was measured at 492 nm 
using a Spectra Max Gemini plate reader from Molecular Devices.  The reaction is based 
on the production of NADH and pyruvate from NAD and lactate by LDH.  This reaction 
is coupled to Dase-catalyzed reoxidation of NADH to NAD and reduction of INT to red 
colored formazan which is read at 492 nm.  The intensity of the red color is proportional 
to the concentration of lactate in the sample.   
 
Activity of Lactate Dehydrogenase 
 
Mice were euthanized, brains (excluding cerebellum) were collected, 
homogenized and were used immediately to determine LDH activity, following the 
method described by Yen et al. (Yen et al., 1996).  Briefly, the homogenized brain was 
added to a solution containing NADH and incubated at room temperature for 20 minutes.  
Sodium pyruvate (22.7 mM) in 0.1 M potassium phosphate buffer (pH 7.5) was added 
after 20 minutes.  In the assay, the reaction where pyruvate is converted to lactate 
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catalyzed by LDH is followed for two minutes.  The decrease in absorbance (dA/min) at 
340 nm that occurs with the oxidation of NADH to NAD is used for calculating the LDH 
activity using the extinction coefficient of 6.22 mM-1cm-1 for NADH.  The activity was 
repeated in three independent experiments, each in triplicate. 
 
Activity of Pyruvate Dehydrogenase 
 
The assay is based on the link between the NADH produced by PDH to reduction 
of the dye INT and was performed as described by Elnageh & Gaitonde (Elnageh and 
Gaitonde, 1988).  Briefly, the final reaction mixture of 1 ml volume consisted of 50 mM 
Tris-HCL, 0.5 mM EDTA and 0.2% (wt/vol) Triton X-100 (pH 7.8), 100 μg of the brain 
homogenate, 2.5 mM NAD, 0.1 mM CoA, 1 mM MgCl2, 0.1 mM oxalate, 1 mg of bovine 
serum albumin, 0.6 mM INT, 5-7 units of lipoamide dehydrogenase, 0.2 mM TPP and 5 
mM pyruvate.  After the addition of 4 mM TPP the contents were kept at 370C for 5 
minutes.  A stable baseline at 500 nm was obtained for the reaction mixture.  The reaction 
was started by adding 100 mM pyruvate.  The absorbance of the mixture at 500 nm was 
recorded at the beginning and again after the reaction had been underway for 5 minutes at 
370C.  Data was obtained from six animals from each genotype. 
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RESULTS 
 
The concentration of lactate in brain homogenate from 14-16 month old APP/PS-
1 mice was significantly increased (p < 0.01) in comparison with its age matched WT 
mice (Figure 4.1).   The activity of lactate dehydrogenase, an enzyme that catalyzes the 
conversion of pyruvate to lactate, was also significantly increased (p < 0.001) in the brain 
homogenate of 14-16 month old APP/PS-1 mice, when compared to its age matched WT 
mice (Figure 4.2).  These results indicate that glycolytic activity is increased in APP/PS-1 
mice. 
Pyruvate dehydrogenase (PDH) catalyzes the conversion of pyruvate to Acetyl-
CoA, which then enters the tri-carboxylic cycle.  Decreased activity of PDH would lead 
to accumulation of pyruvate, which can be converted to lactate by lactate dehydrogenase.  
The activity of PDH was significantly decreased even in 3 month old mice of APP/PS-1 
genotype when compared to WT mice.  This decrease in activity was further exaggerated 
at 14-16 months of age in APP/PS-1 mice (Figure 4.3).   
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Figure 4.1 Increased lactate levels in APP/PS-1 mice.
Brains (excluding cerebellum) were homogenised, centrifuged and the supernatant used for
estimation of lactate.
All measurements were performed from six animals. *, p < 0.05, compared with the age-
matched WT.
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Figure 4.2 Increased activity of lactate dehydrogenase in APP/PS-1 mice.
Brains (excluding cerebellum) were homogenised, centrifuged and the supernatant used for
estimation of LDH activity
All measurements were performed from six animals. ***, p < 0.001, compared with the
age-matched WT.
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Figure 4.3 Decreased activity of pyruvate dehydrogenase in APP/PS-1 mice.
Brains (excluding cerebellum) were homogenised, centrifuged and the supernatant used for
estimation of PDH activity
All measurements were performed from six animals. **, p < 0.01, compared with the age-
matched WT.
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DISCUSSION 
 
Numerous in vitro studies on various components of cerebral glucose metabolism 
of AD have revealed a reduced activity of different enzymes involved in glucose and 
energy metabolism.  There is also an impairment of glucose carriers in brain endothelial 
cells.  Therefore reduced glucose uptake and/or metabolism in the brain has been 
suggested as a reason for neurodegenerative loss of neurons and synaptic connections 
(Bigl et al., 2003; Bigl et al., 1999).  The glucose uptake studies using of [18F] 
deoxyglucose have demonstrated reduced glucose levels in AD brain.  However, these 
findings do not address whether the decreased deoxyglucose uptake reflects a limited 
metabolic capacity of the brain or a mere reduction in energy demand of a diseased organ  
(Bigl et al., 1999).   
The increase in lactate levels APP/PS-1 mice at 14-16 months of age suggests an 
upregulated glycolytic activity.  The increased lactate levels implicate a compensation for 
the reduced mitochondrial function found in APP/PS-1 mice (Chapter two) 
(Anantharaman et al., 2006).  Increase in glycolytic activity in the event of reduction in 
mitochondrial function is well documented in many tumors (Pedersen, 2007; Schoonen et 
al., 1990; Warburg, 1956; Wu et al., 2007).  Our results are consistent with report of 
lactate transported from astrocytes by astrocyte-neuron shuttle (ANLSH) (Schurr, 2006) 
which under the conditions of mitochondrial respiratory inhibition by nitric oxide exhibit 
high lactate levels (Almeida et al., 2001).  Being the most numerous nonneuronal cell 
type in the central nervous system (Tower and Young, 1973) and also being the first cell 
to encounter glucose from blood, the possibility of astrocyte being the source of neuronal 
lactate is highly likely.  Although SH-SY5Y cells are cancer cells which are dependent 
on glucose for energy metabolism, increased lactate levels observed in SH-SY5Y cells 
(Chapter three), a predominantly neuronal cells line argues that neurons by themselves 
could be a source of increased lactate observed in APP/PS-1 mice.  
The increased lactate levels were consistent with increase in LDH activity in 
APP/PS-1 mice.   This is consistent with the documented findings from the brains of AD 
patients (Bigl et al., 1999).  Although the specific advantage of increased LDH activity in 
the brain is unclear, a suppression of LDH resulted in decreased tumorigenicity in 
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malignant cells along with increased mitochondrial respiration (Fantin et al., 2006).  LDH 
utilizes NADH and produces NAD in the process of catalyzing the conversion of 
pyruvate to lactate.  NADH being the reducing equivalent for the mitochondrial electron 
transport chain, its usage by LDH may lead to depression in mitochondrial respiration 
and thereby the energy production.  Further, as NAD is regenerated, it fuels glycolysis 
and results in increased pyruvate production.   
An additional way by which lactate levels can increase is in the presence of 
compromised PDH activity.  Pyrvuate is converted to acetyl-CoA by PDH.  In the event 
of decreased PDH activity as observed in APP/PS-1 mice, pyruvate gets accumulated.  
The fast kinetics of LDH ensures that pyruvate is converted to lactate (Fantin et al., 
2006).  PDH is a critical enzyme for carbohydrate oxidation, present in minimal excess in 
the brain, and is closely involved in synaptic plasticity (Sorbi et al., 1983).  A decrease in 
activity of PDH has been documented in AD (Perry et al., 1977).  Acetyl-CoA, the 
product of pyruvate oxidation by PDH is necessary for the synthesis of acetyl choline, a 
neurotransmitter known to be involved in learning and memory processes.  Therefore, 
any dysfunction of PDH would lead to decreased acetyl-CoA production and may lead to 
the cognitive decline associated with AD. 
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CHAPTER FIVE 
 
SUMMARY AND FUTURE STUDIES 
 
As AD brain is under pronounced oxidative stress, and mitochondria is the major 
source of superoxide radicals, a dysfunction of MnSOD may exacerbate the progression 
of the disease.  The studies presented in this work were carried out with the goal of 
adding more knowledge on the status of nitration and thereby the activity of MnSOD in 
AD brain.  The data presented in this dissertation strongly suggest that inactivation of 
MnSOD contributes to mitochondrial dysfunction and subsequent enhancement of 
glycolytic activity.  Although it is well recognized that impaired mitochondrial function 
can be compensated by an upregulation of glycolysis, to my knowledge, the data 
presented here is the first report on the essential role of an anti-oxidant enzyme 
influencing this process.  This is supported by the data obtained when addressing the 
hypotheses, 1) MnSOD is nitrated and inactivated in association with Aβ deposition. 2) 
Nitrative inactivation of MnSOD plays an important role in the impairment of 
mitochondrial respiratory function resulting in alteration of energy metabolism. 3) The 
impairment of mitochondrial respiration observed in APP/PS-1 mice was also associated 
with an increase in glycolytic activity.  
Nitrative inactivation of MnSOD in the presence of accelerated deposition of Aβ 
was studied using homozygous knock-in APPNLh/NLh x PS-1P264L/P264L mouse. 
MnSOD was nitrated with an associated reduction in the activity as Aβ deposition 
increased in the brains of these mice.  Nitration and inactivation of MnSOD showed a 
strong correlation with age.  Aβ deposition was detectable at the age of 6 months and by 
14 months deposition was prominent and widespread encompassing neocortex and 
hippocampus.  The finding of increased nitration of MnSOD in an age dependent manner 
suggested that Aβ deposition may be a cause for MnSOD nitration.  This is supported by 
the findings of increased nitrotyrosine immunoreactivity in cultured cells treated with β-
amyloid and in rats subjected to intracerebroventricular infusion of β-amyloid (Mattson et 
al., 1997; Tran et al., 2003).  Further, studies showing that Aβ induced accumulation of 
mitochondrial peroxynitrite (Keller et al., 1998; Mattson et al., 1997), argues for the 
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possibility that Aβ deposition with age is the cause of MnSOD nitration in APP/PS-1 
mice.  Although the presence of MnSOD nitration by 3 months in APP/PS-1 mice in the 
absence of any observable Aβ deposits argues against the notion of Aβ induced nitration, 
more recently, report on increase in levels of protein nitration in inferior parietal lobule 
(IPL) and hippocampus of mild cognitive impairment (MCI) patients implicate a 
prominent role for protein nitration during the early events of AD (Butterfield et al., 
2007).  
Inactivation of MnSOD in association with nitration is consistent with previous 
studies on peroxynitrite mediated nitration of critical tyrosine residues of MnSOD 
leading to its inactivation (MacMillan-Crow et al., 1998; Yamakura et al., 1998).  In 
addition, our data from SH-SY5Y cells showing increased nitration of MnSOD upon 
peroxynitrite treatment suggests that in APP/PS-1 mice, nitrative inactivation of MnSOD 
might have occurred by Aβ deposition induced peroxynitrite production.  APP/PS-1 mice 
exhibited a decrease in mitochondrial respiration mediated through complex I, as 
measured by oxygen consumption of isolated mitochondria. The reduction was 
significant at 9 and 12 months of age when compared to age-matched WT mice.  As 
APP/PS-1 mice had reduced MnSOD activity, prior to the observed reduction in 
respiration, it is possible that reduction of MnSOD activity may be a cause for the 
observed reduction in respiration.  This is supported by previous data from our lab 
demonstrating that MnSOD selectively protects state 3 respiration activity through 
complex I substrates and prevented complex I inactivation (Yen et al., 1999).  Further, 
Kokoszka et al., (Kokoszka et al., 2001) demonstrated in sod 2 +/-, a impaired 
mitochondrial respiration adding credence to the possible role of reduced activity of 
MnSOD in APP/PS-1 in decreasing the mitochondrial respiration.  The data that we 
obtained from SH-SY5Y cells, treated with peroxynitrite, demonstrating reduced 
complex I activity and mitochondrial function, which was ameliorated by SOD mimetic 
and reproduced by MnSOD siRNA strongly suggest a predominant role for MnSOD in 
altering respiration.  Although there are multiple targets for peroxynitrite in mitochondria 
(Cassina and Radi, 1996; MacMillan-Crow et al., 1998; Rusak et al., 2006; Yamakura et 
al., 1998), our result demonstrates that MnSOD is an early target in the process of 
peroxynitrite-induced mitochondrial dysfunction. MnSOD was inactivated at 1 μM 
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peroxynitrite, but respiration was inhibited at 10- fold higher concentrations.  Given the 
transient nature of peroxynitrite in biological systems, the early inactivation of MnSOD, 
an important anti-oxidant enzyme in the mitochondria, is of immense importance. 
MnSOD can inhibit peroxynitrite formation in the mitochondria (Radi et al., 1994), but 
its inactivation can possibly lead to an increase in intramitochondrial superoxide levels 
and additional generation of peroxynitrite (MacMillan-Crow et al., 1996).  This can 
propagate the initial damaging event that leads to mitochondrial dysfunction (Radi et al., 
1994).  Our results suggested that MnSOD is inactivated followed by respiratory 
impairment.  However, the efficient functioning of the mitochondrial respiratory chain 
depends on the supply of reducing equivalents (NADH & FADH2) chiefly from 
tricaboxylic cycle.  Any dysfunction of the enzymes involved in Kreb’s cyle would be 
expected to result in decreased production of reducing equivalents and an impaired 
mitochondrial respiration.  Peroxynitrite being a potent oxidant might also affect the 
enzymes of Kreb’s cycle.  Effect of peroxynitrite on the activity of isocitrate 
dehydogenase, alpha-ketoglutarate dehydrogenase, malate dehydrogenase and succinate 
dehyrogenase involved in production of NADH and FADH2 needs to be investigated.  
A compensatory upregulation of glycolytic activity has been observed in the event 
of decreased mitochondrial function.  In APP/PS-1 mice, we observed increased levels of 
lactate, an index of increased glycolysis.  This, when taken together with the data of 
reduced activity of MnSOD, decreased mitochondrial respiration in APP/PS-1 mice and 
the finding of MnSOD in maintaining the mitochondrial function suggest that MnSOD is 
influencing the metabolic switch to glycolysis in APP/PS-1 mice.  This notion is 
supported by the data from SH-SY5Y cells which showed increased levels of lactate on 
peroxynitrite treatment, preventable by SOD mimetic and reproduced by MnSOD siRNA. 
Severe impairment of the ability to oxidize substrates through pyruvate dehydrogenase 
(PDH), tricarboxylic acid cycle or electron transport chain are likely to lead to 
accumulation of lactate.  In this study, we encountered a decreased activity of PDH and 
impaired mitochondrial function in APP/PS-1 mice and also in SH-SY5Y cells treated 
with peroxynitrite.  These might have resulted in increased lactate levels, without an 
actual increase in glycolytic activity.  Lactate also arises from amino acid alanine, which 
is converted to pyruvate by alanine amino transferease.  But, in our system there is 
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reduced activity of PDH.  Hence, pyruvate cannot enter the TCA cycle and is instead 
converted to lactate.  Acetyl CoA formed from beta oxidation of fatty acids can also 
contribute to increased lactate levels by inhibiting PDH.  This inhibition would lead 
accumulation of pyruvate that is converted to lactate.  In this dissertation work, we have 
not addressed the contribution from these respective sources.  Therefore, to add credence 
to our finding of increased glycolysis, the contribution to lactate levels by amino acids 
and fatty acids should be quantified.  Further, by redox proteomics approach, enzymes 
like enolase and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) are shown to be 
nitrated in the brains of AD patients.  If this is true, we should have encountered a 
decrease in glycolytic activity, which we did not.  Perhaps, the treatment regimen that 
was followed in this dissertation (24 hours treatment of SH-SY5Y cells with 
peroxynitrite) was not sufficient to cause nitration of glycolytic enzymes or probably 
glycolytic enzymes are in abundance, to keep the glycolysis active, even in the presence 
of nitrated and possibly inactivated proteins.  
As mitochondrial function is a prerequisite for the majority of ATP produced in a 
cell, any dysfunction would be expected to result in a decreased ATP levels.  A 
compensatory increase in glycolytic activity may offset ATP loss, which was the case, as 
we observed comparable ATP levels in control and peroxynitrite treated SH-SY5Y cells. 
As in many tumors, where an increase in glycolytic activity is supported by enhanced 
glucose uptake into the cells, peroxynitrite treated SH-SY5Y cells showed significantly 
increased concentrations of glucose when compared to untreated cells.  Further, our 
observation of decreased respiration, decreased complex I activity and increased lactate 
in the MnSOD heterozygous knock-out mice adds credence to the hypothesis that 
decreased activity of MnSOD is contributing to a switch from oxidative phosphorylation 
to glycolysis in AD.  
The finding of enhanced glycolysis in our AD mouse model is in contrast to that 
of human AD patients, where an impaired glucose metabolism has been reported.  The 
following reasons could explain the apparent inconsistency between these studies,  
1. The human data is based on glucose uptake studies using PET imaging.  This does 
not clearly indicate whether there is a true limited metabolic capacity of the brain 
or a mere reduction in energy demand of a diseased organ (Bigl et al., 1999). 
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1. Further, the neuronal loss encountered in AD may also account for reduced 
glucose uptake or probably the loss of neurons is so abundant that a compensatory 
enhancement of glycolytic activity in the remaining neurons may not be sufficient 
to manifest as an increase.  
2. The age group of APP/PS-1 mice (14 - 16 months) used to analyze the lactate 
levels may not be comparable to aged human AD patients.  The increase in 
glycolytic activity is perhaps occurring at a very early age in humans, which if 
found might be utilized as a potential target for modulating the progression of 
AD.  
3. APP/PS-1 mice have not been shown to develop neurofibrillary tangles, which 
may be necessary to reproduce the metabolic changes occurring in humans.  
To further elucidate the role of MnSOD in altering the mitochondrial function and 
glycolytic activity, it would be worthwhile to investigate in vivo by injecting SOD 
mimetic in APP/PS-1 mice.  Primary neurons from APP/PS-1 mice exhibit increased 
colocalization of nitrotyrosine with MnSOD, decreased mitochondrial function and 
increased susceptibility to Aβ treatment (Sompol et al., 2008).  So it would be interesting 
to investigate whether these primary neurons have increased glycolytic activity.  Further, 
APP/PS-1 mice do not develop neurofibrillary tangles and show neuronal loss, it does not 
recapitulate the complete AD pathology encountered in human beings.  Therefore, to 
make the findings of this study more relevant to human AD, a triple transgenic mouse 
exhibiting all the pathological hallmarks of human AD could be utilized to study the 
effect of MnSOD on glycolysis.  
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Figure 5.1 Hypothetical model suggested from the data obtained.
Nitric oxide produced by surrounding microglia or astrocytes or by the neurons itself,
diffuse into the mitochondria and inhibit complex IV. Inhibition of complex IV lead to
electron leak and superoxide production. Superoxide can react with nitric oxide to result in
peroxynitrite formation. MnSOD is nitrated and inactivated at low concentrations of
peroxynitrite produced leading to accumulation of superoxide and peroxynitrite.
Increasing concentrations of these can inhibit respiratory chain and thereby the
mitochondrial respiration. Inhibition of mitochondrial respiration leads to increase in
glycolytic activity to offset any ATP loss. Black dashed lines and words in black – known
in the literature; red arrows and words in red – data obtained from this dissertation; yellow
box with words in black – indicated in the existing literature but not proven.
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